

TABLE 4: Transgenic/gene KO mice or rats for identifying chemoprevention efficacy.

Genes	Target tissues	Genetic lesions	Induced tumors
<i>Min</i>	Intestine	Heterozygous <i>Apc</i> 2549	AD
<i>Apc</i>	Intestine	Heterozygous <i>Apc</i> 1638	AD
MLH1/ <i>Apc</i> 1638	Intestine	Heterozygous MLH1 and <i>Apc</i> 1638	AD
<i>Msh2/Min</i>	Intestine	Heterozygous MLH2 and <i>Apc</i> 2549	AD
<i>pim</i>	Lymphatic system	Amplified <i>pim-1</i>	T-cell lymphoma
TG:AC	Skin	Ha- <i>ras</i> mutation	PAP, possibly carcinoma
TSG-p53	Skin	Heterozygous p53 deficient	PAP, possibly carcinoma
A/JxTSG-p53	Lung	Heterozygous p53 deficient	AD
A/JxUL53	Lung	Heterozygous p53 mutant	AD
TGF β 1	Liver, lung	Heterozygous TGF β 1 mutant	AD, carcinoma
v-Ha- <i>ras</i>	Skin	Ha- <i>ras</i> + Human keratin K-1	HP, PAP
K14-HPV16	Skin	HPV-infected (K14-HPV16 heterozygote), estradiol-treated + SV40 T-antigen	PAP, condyloma
	Cervix	HPV-infected (K14-HPV16 heterozygote), estradiol-treated + SV40 T-antigen	Dysplasia
rPB-SV40 Tag transgene	Prostate	SV40 large tumor T antigen (Tag)	Dysplasia, AD, ADC (TRAMP model)
C3(1)-SV40	Prostate	Heterozygous rat prostate steroid binding gene [C3(1)] + SV40 T-antigen	Dysplasia, AD, ADC
	Breast	Heterozygous rat prostate steroid binding gene [C3(1)] + SV40 T-antigen	ADC
<i>ErbB-2</i>	Gall bladder	BK. <i>ErbB-2</i>	AD, ADC
	Breast	Jcl/SD-TgN(H <i>ras</i> Gen)128Ncc	ADC
Human c-Ha- <i>ras</i>	Urinary bladder	Jcl/SD-TgN(H <i>ras</i> Gen)128Ncc	TCC
	Prostate	Jcl/SD-TgN(H <i>ras</i> Gen)128Ncc	ADC, PIN
	Tongue	Human prototype c-Ha- <i>ras</i> gene with its own promoter region	PAP, SCC

AD, adenoma; ADC, adenocarcinoma; HP, hyperplasia; HPV, human papilloma virus; PAP, squamous cell papilloma; PIN, prostate intraepithelial neoplasia; TCC, transitional cell carcinoma; TGF, transforming growth factor.

different mechanisms of action are combined [149]. Such improved activity of inhibition may allow either or both of the agents to be given at lower doses, thereby reducing the toxic potential. Examples of chemical combinations producing positive results in experimental animal models include all-*trans-N*-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen in the rat mammary gland [151] and 2-dinuoromethylorinithine (DFMO) and piroxicam in the rat colon [152, 153]. The identification and evaluation of other effective agent combinations is an interesting and important research effort for chemopreventive agent development [154, 155]. Since different treatment schedules of the two drugs can be compared and evaluated for synergism, additivity, or antagonism using a quantitative method based on the median-effect principle of Chou and Talalay [156–159] can identify the ideal combination treatment for obtaining an improved effect in comparison to a single exposure of the potential chemopreventive agent [160–162].

9. Intermediate Biomarkers

Carcinogenesis proceeds through a very long preclinical period. The collective hope is that multiple opportunities exist for chemoprevention to arrest or reverse progression

towards malignancy. Intermediate biomarkers of malignant neoplasms are the phenotypic, genotypic, and molecular changes that occur during carcinogenesis [69]. An important component of chemopreventive agent development research is the identification and characterization of intermediate biomarkers that may serve as surrogate end points for cancer incidence reduction in chemoprevention clinical trials [163]. Such efforts are critical to the progress of chemoprevention and have the potential for cost-effective development of chemopreventive research [5, 6, 69]. Biomarkers include proliferation, apoptosis, growth factors and their receptors, genetic alterations, and so forth in the target tissues [162, 164, 165]. In the hope of faster progress with fewer subjects and lower total cost, much effort is being expended on the search for reliable biomarkers to predict the likelihood of developing cancer and/or to signal the effectiveness of chemopreventive therapy [166]. Considerable attention has been paid to identifying those markers that can act as surrogate markers for cancer development since favorable modulation of the surrogate end-point biomarker may demonstrate the effectiveness of a putative preventive treatment. However, the complexity of the biology challenges the ability to measure the effectiveness of attempts to arrest or reverse carcinogenesis, other than through costly and

time-consuming prospective trials with the disease state as the endpoint. Despite much work, to date no prehistological biological or molecular intermediate marker has yet been validated for sporadic cancers.

For chemoprevention of prostate cancer [167] and other types of cancer, natural and synthetic agents that may suppress, reverse, or regress precancer and delay progression to invasive cancer can be used [77]. Epidemiological evidence suggests that environmental factors, such as diet, play a role in the development and progression of prostate cancer. The number of potential protective dietary compounds or whole dietary products that are indicated to have preventive effects is piling up and demands further evaluation. To face this scientific field, a strategy that combines prostate-specific antigen (PSA)-based clinical trials with experimental human xenograft studies to evaluate potential chemopreventive agents against prostatic cancer is proposed [168, 169]. PSA for prostate adenocarcinoma, even though has relatively poor specificity, is cheap and easily followed with minimally invasive procedures.

10. Future Direction

Epidemiologic evidence suggests that green tea polyphenols reduce the risk of some forms of cancer, while data for other commonly used phytochemicals is less convincing. Part of the problem lies in precise quantitation of foodborn phytochemicals where multiple dietary sources of a particular phytochemical are involved, as in recent studies of dietary quercetin on the prevention of heart disease. Future investigations may focus on specific foodborn phytochemicals and/or botanicals capable of intervening in critical pathways in carcinogenesis as indicated by the possible use of "natural" NSAIDs in the prevention of CRC and the soy-based phytoestrogens in the prevention of breast cancer. Much is to be learned by collaboration between cancer researchers and ethnopharmacologists for probing dietary prevention of cancer. In addition, the development and validation of new in vitro and in vivo assays of high predictive value for discovering agents with human chemopreventive potential is needed. Care, however, is needed when extrapolating in vitro data to in vivo models because it cannot be assumed that the effects seen when cells are exposed directly to active compounds that would be candidate chemopreventive agents will be seen when they are consumed in the diet. We should investigate whether they are capable of distribution throughout the body when they are absorbed after ingestion. The understanding of the molecular and cellular processes, such as gene and protein expression, apoptosis, angiogenesis, signal transduction, involved in carcinogenesis is rapidly increasing. Currently several translational studies using phytochemicals and bioactive compounds, such as indole-3-carbinol [170], ellagitannins [171], sulforaphane [172], lycopene [173], diallyl trisulfide [174], omega-3 fatty acids [175], proanthocyanidins [176], green tea polyphenols [177], genistein [178], silymarin [179], and curcumin [180, 181], from plants are underway.

Acknowledgments

This review was based on studies supported in part by a Grant-in Aid for the 3rd Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan; the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan; the Grants-in-Aid for Scientific Research (nos. 18592076, 17015016, and 18880030) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and the Grant (S2007-9 and H2008-12) for the Project Research from High-Technology Center of Kanazawa Medical University.

References

- [1] A. Jemal, R. Siegel, E. Ward, et al., "Cancer statistics, 2008," *CA :Cancer Journal for Clinicians*, vol. 58, no. 2, pp. 71-96, 2008.
- [2] H. E. Karim-Kos, E. de Vries, I. Soerjomataram, V. Lemmens, S. Siesling, and J. W. W. Coebergh, "Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s," *European Journal of Cancer*, vol. 44, no. 10, pp. 1345-1389, 2008.
- [3] J. H. Weisburger, "Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids," *The American Journal of Clinical Nutrition*, vol. 53, supplement 1, pp. 226S-237S, 1991.
- [4] T. Tanaka, "Chemoprevention of oral carcinogenesis," *European Journal of Cancer Part B*, vol. 31, no. 1, pp. 3-15, 1995.
- [5] T. Tanaka, "Effect of diet on human carcinogenesis," *Critical Reviews in Oncology/Hematology*, vol. 25, no. 2, pp. 73-95, 1997.
- [6] T. Tanaka, "Chemoprevention of human cancer: biology and therapy," *Critical Reviews in Oncology/Hematology*, vol. 25, no. 3, pp. 139-174, 1997.
- [7] T. Tanaka, "Chemoprevention of colon carcinogenesis by non-nutritive compounds in foods," in *Sonderdruck aus Deutsche Forschungsgemeinschaft: Carcinogenic and Anticarcinogenic Factors in Food Senate Commission on Food Safety*, G. Eisenbrand, A. D. Dayan, P. S. Elias, W. Grunow, and J. Schlatter, Eds., pp. 365-391, Wiley-VCH, Weinheim, Germany, 2000.
- [8] D. M. Eisenberg, R. B. Davis, S. L. Ettner, et al., "Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey," *Journal of the American Medical Association*, vol. 280, no. 18, pp. 1569-1575, 1998.
- [9] K. A. Steinmetz and J. D. Potter, "Vegetables, fruit, and cancer. I. Epidemiology," *Cancer Causes and Control*, vol. 2, no. 5, pp. 325-357, 1991.
- [10] K. A. Steinmetz and J. D. Potter, "Vegetables, fruits, and cancer; II. Mechanisms," *Cancer Causes Control*, vol. 2, no. 6, pp. 427-442, 1991.
- [11] T. Tanaka, S. Miyamoto, R. Suzuki, and Y. Yasui, "Chemoprevention of colon carcinogenesis by dietary non-nutritive compounds," *Current Topics in Nutraceutical Research*, vol. 4, no. 2, pp. 127-152, 2006.
- [12] T. Tanaka and S. Sugie, "Inhibition of colon carcinogenesis by dietary non-nutritive compounds," *Journal of Toxicologic Pathology*, vol. 20, no. 4, pp. 215-235, 2008.

- [13] V. Benetou, P. Orfanos, P. Lagiou, D. Trichopoulos, P. Boffetta, and A. Trichopoulou, "Vegetables and fruits in relation to cancer risk: evidence from the Greek EPIC cohort study," *Cancer Epidemiology Biomarkers and Prevention*, vol. 17, no. 2, pp. 387–392, 2008.
- [14] G. Corona, M. Deiana, A. Incani, D. Vauzour, M. A. Dessi, and J. P. E. Spencer, "Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects," *Biochemical and Biophysical Research Communications*, vol. 362, no. 3, pp. 606–611, 2007.
- [15] V. Goulas, V. Exarchou, A. N. Troganis, et al., "Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells," *Molecular Nutrition & Food Research*. In press.
- [16] H. K. Hamdi and R. Castellon, "Oleuropein, a non-toxic olive iridoid, is an anti-tumor agent and cytoskeleton disruptor," *Biochemical and Biophysical Research Communications*, vol. 334, no. 3, pp. 769–778, 2005.
- [17] I. Andreadou, F. Sigala, E.K. Iliodromitis, et al., "Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress," *Journal of Molecular and Cellular Cardiology*, vol. 42, no. 3, pp. 549–558, 2007.
- [18] W. J. Craig, "Phytochemicals: guardians of our health," *Journal of the American Dietetic Association*, vol. 97, no. 10, supplement 2, pp. S199–204, 1997.
- [19] R. A. Gupta and R. N. DuBois, "Aspirin, NSAIDs, and colon cancer prevention: mechanisms?" *Gastroenterology*, vol. 114, no. 5, pp. 1095–1098, 1998.
- [20] W. E. Smalley and R. N. DuBois, "Colorectal cancer and nonsteroidal anti-inflammatory drugs," *Advances in Pharmacology*, vol. 39, pp. 1–20, 1997.
- [21] K. M. Sheehan, K. Sheahan, P. O'Donoghue, et al., "The relationship between cyclooxygenase-2 expression and colorectal cancer," *Journal of the American Medical Association*, vol. 282, no. 13, pp. 1254–1257, 1999.
- [22] S. Tsuji, M. Tsujii, S. Kawano, and M. Hori, "Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis," *Journal of Experimental and Clinical Cancer Research*, vol. 20, no. 1, pp. 117–129, 2001.
- [23] K. Wakabayashi, "NSAIDs as cancer preventive agents," *Asian Pacific Journal of Cancer Prevention*, vol. 1, no. 2, pp. 97–113, 2000.
- [24] D. Y. Graham and J. L. Smith, "Aspirin and the stomach," *Annals of Internal Medicine*, vol. 104, no. 3, pp. 390–398, 1986.
- [25] P. M. Lynch, "COX-2 inhibition in clinical cancer prevention," *Oncology*, vol. 15, no. 3, supplement 5, pp. 21–26, 2001.
- [26] K. Watanabe, T. Kawamori, S. Nakatsugi, and K. Wakabayashi, "Cox-2 and inos, good targets for chemoprevention of colon cancer," *BioFactors*, vol. 12, no. 1–4, pp. 129–133, 2000.
- [27] T. Kawamori, C. V. Rao, K. Seibert, and B. S. Reddy, "Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis," *Cancer Research*, vol. 58, no. 3, pp. 409–412, 1998.
- [28] R. S. Bresalier, R. S. Sandler, H. Quan, et al., "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial," *The New England Journal of Medicine*, vol. 352, no. 11, pp. 1092–1102, 2005.
- [29] Y. J. Surh, K. S. Chun, H. H. Cha, et al., "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF- κ B activation," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 480–481, pp. 243–268, 2001.
- [30] A. Goel, A. B. Kunnumakkara, and B. B. Aggarwal, "Curcumin as "Curecumin": from kitchen to clinic," *Biochemical Pharmacology*, vol. 75, no. 4, pp. 787–809, 2008.
- [31] A. Murakami and H. Ohigashi, "Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals," *International Journal of Cancer*, vol. 121, no. 11, pp. 2357–2363, 2007.
- [32] M.-T. Huang, T. Lysz, T. Ferraro, T. F. Abidi, J. D. Laskin, and A. H. Conney, "Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis," *Cancer Research*, vol. 51, no. 3, pp. 813–819, 1991.
- [33] M.-T. Huang, R. C. Smart, C.-Q. Wong, and A. H. Conney, "Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate," *Cancer Research*, vol. 48, no. 21, pp. 5941–5946, 1988.
- [34] T. Tanaka, H. Makita, M. Ohnishi, et al., "Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of β -carotene," *Cancer Research*, vol. 54, no. 17, pp. 4653–4659, 1994.
- [35] C. V. Rao, A. Rivenson, B. Simi, and B. S. Reddy, "Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound," *Cancer Research*, vol. 55, no. 2, pp. 259–266, 1995.
- [36] J. R. Carlson, B. A. Bauer, A. Vincent, P. J. Limburg, and T. Wilson, "Reading the tea leaves: anticarcinogenic properties of (-)- epigallocatechin-3-gallate," *Mayo Clinic Proceedings*, vol. 82, no. 6, pp. 725–732, 2007.
- [37] P. Greenwald, "Clinical trials in cancer prevention: current results and perspectives for the future," *The Journal of Nutrition*, vol. 134, no. 12, pp. 3507S–3512S, 2004.
- [38] D. A. August, J. Landau, D. Caputo, J. Hong, M.-J. Lee, and C. S. Yang, "Ingestion of green tea rapidly decreases prostaglandin E₂ levels in rectal mucosa in humans," *Cancer Epidemiology Biomarkers and Prevention*, vol. 8, no. 8, pp. 709–713, 1999.
- [39] P. Saiko, A. Szakmary, W. Jaeger, and T. Szekeres, "Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?" *Mutation Research/Reviews in Mutation Research*, vol. 658, no. 1–2, pp. 68–94, 2008.
- [40] J. Gusman, H. Malonne, and G. Atassi, "A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol," *Carcinogenesis*, vol. 22, no. 8, pp. 1111–1117, 2001.
- [41] M. Jang, L. Cai, G. O. Udeani, et al., "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes," *Science*, vol. 275, no. 5297, pp. 218–220, 1997.
- [42] M. Kaur and R. Agarwal, "Silymarin and epithelial cancer chemoprevention: how close we are to bedside?" *Toxicology and Applied Pharmacology*, vol. 224, no. 3, pp. 350–359, 2007.
- [43] G. M. Raso, R. Meli, G. Di Carlo, M. Pacilio, and R. Di Carlo, "Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1," *Life Sciences*, vol. 68, no. 8, pp. 921–931, 2001.
- [44] R. Agarwal, S. K. Katiyar, D. W. Lundgren, and H. Mukhtar, "Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice," *Carcinogenesis*, vol. 15, no. 6, pp. 1099–1103, 1994.

- [45] G. Deep and R. Agarwal, "Chemopreventive efficacy of silymarin in skin and prostate cancer," *Integrative Cancer Therapies*, vol. 6, no. 2, pp. 130–145, 2007.
- [46] H. Kohno, T. Tanaka, K. Kawabata, et al., "Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats," *International Journal of Cancer*, vol. 101, no. 5, pp. 461–468, 2002.
- [47] Y. Yanai, H. Kohno, K. Yoshida, et al., "Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats," *Carcinogenesis*, vol. 23, no. 5, pp. 787–794, 2002.
- [48] H. Kohno, R. Suzuki, S. Sugie, H. Tsuda, and T. Tanaka, "Dietary supplementation with silymarin inhibits 3,2'-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats," *Clinical Cancer Research*, vol. 11, no. 13, pp. 4962–4967, 2005.
- [49] M. M.-Y. Chan, C.-T. Ho, and H.-I. Huang, "Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production," *Cancer Letters*, vol. 96, no. 1, pp. 23–29, 1995.
- [50] E. Tjendraputra, V. H. Tran, D. Liu-Brennan, B. D. Roufogalis, and C. C. Duke, "Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells," *Bioorganic Chemistry*, vol. 29, no. 3, pp. 156–163, 2001.
- [51] K. Singletary, C. MacDonald, and M. Wallig, "Inhibition by rosemary and carnosol of 7,12-dimethylbenz[*a*] anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation," *Cancer Letters*, vol. 104, no. 1, pp. 43–48, 1996.
- [52] Y. Shukla and M. Singh, "Cancer preventive properties of ginger: a brief review," *Food and Chemical Toxicology*, vol. 45, no. 5, pp. 683–690, 2007.
- [53] S. Miyamoto, Y. Yasui, T. Tanaka, H. Ohigashi, and A. Murakami, "Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice," *Carcinogenesis*, vol. 29, no. 5, pp. 1057–1063, 2008.
- [54] M. X. Tang, K. Ogawa, M. Asamoto, et al., "Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells," *Cancer Science*, vol. 98, no. 4, pp. 471–477, 2007.
- [55] R. Suzuki, H. Kohno, A. Murakami, et al., "Citrus nobiletin inhibits azoxymethane-induced large bowel carcinogenesis in rats," *BioFactors*, vol. 21, no. 1–4, pp. 111–114, 2004.
- [56] A. Murakami, Y. Nakamura, K. Torikai, et al., "Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion mice," *Cancer Research*, vol. 60, no. 18, pp. 5059–5066, 2000.
- [57] A. Murakami, T. Tanaka, J.-Y. Lee, et al., "Zerumbone, a sesquiterpene in subtropical ginger, suppresses skin tumor initiation and promotion stages in ICR mice," *International Journal of Cancer*, vol. 110, no. 4, pp. 481–490, 2004.
- [58] T. Tanaka, M. Shimizu, H. Kohno, et al., "Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from *Zingiber zerumbet*," *Life Sciences*, vol. 69, no. 16, pp. 1935–1945, 2001.
- [59] K. Yoshida, T. Tanaka, Y. Hirose, et al., "Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats," *Cancer Letters*, vol. 221, no. 1, pp. 29–39, 2005.
- [60] T. Tanaka, H. Kohno, R. Shimada, et al., "Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats," *Carcinogenesis*, vol. 21, no. 6, pp. 1183–1189, 2000.
- [61] R. Suzuki, H. Kohno, S. Sugie, et al., "A polyisoprenylated benzophenone garcinol inhibits azoxymethane-induced rat colon carcinogenesis," in *Carcinogenesis and Modification of Carcinogenesis*, T. Tanaka and H. Tsuda, Eds., pp. 187–198, Research Signpost, Kerala, India, 2005.
- [62] M. Kim, S. Miyamoto, Y. Yasui, T. Oyama, A. Murakami, and T. Tanaka, "Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice," *International Journal of Cancer*, vol. 124, no. 2, pp. 264–271, 2009.
- [63] H. Liu, A. T. Dinkova-Kostova, and P. Talalay, "Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 41, pp. 15926–15931, 2008.
- [64] P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara, and B. B. Aggarwal, "Curcumin and cancer: an "old-age" disease with an "age-old" solution," *Cancer Letters*, vol. 267, no. 1, pp. 133–164, 2008.
- [65] K. B. Harikumar and B. B. Aggarwal, "Resveratrol: a multitargeted agent for age-associated chronic diseases," *Cell Cycle*, vol. 7, no. 8, pp. 1020–1037, 2008.
- [66] T. A. Zykova, F. Zhu, X. Zhai, et al., "Resveratrol directly targets COX-2 to inhibit carcinogenesis," *Molecular Carcinogenesis*, vol. 47, no. 10, pp. 797–805, 2008.
- [67] R. Agarwal, C. Agarwal, H. Ichikawa, R.P. Singh, and B.B. Aggarwal, "Anticancer potential of silymarin: from bench to bed side," *Anticancer Research*, vol. 26, no. 6B, pp. 4457–4498, 2006.
- [68] D. W. Rosenberg, C. Giardina, and T. Tanaka, "Mouse models for the study of colon carcinogenesis," *Carcinogenesis*, vol. 30, no. 2, pp. 183–196, 2009.
- [69] Y. Yasui, M. Kim, T. Oyama, and T. Tanaka, "Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets," *Current Enzyme Inhibition*, vol. 5, no. 1, pp. 1–26, 2009.
- [70] Y. Yasui, M. Kim, and T. Tanaka, "PPAR ligands for cancer chemoprevention," *PPAR Research*, vol. 2008, Article ID 548919, 10 pages, 2008.
- [71] N. Khan, F. Afaq, and H. Mukhtar, "Cancer chemoprevention through dietary antioxidants: progress and promise," *Antioxidants and Redox Signaling*, vol. 10, no. 3, pp. 475–510, 2008.
- [72] Y.-J. Surh, J. K. Kundu, H.-K. Na, and J.-S. Lee, "Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals," *The Journal of Nutrition*, vol. 135, no. 12, pp. 2993S–3001S, 2005.
- [73] T. Tanaka, T. Kojima, T. Kawamori, and H. Mori, "Chemoprevention of digestive organs carcinogenesis by natural product protocatechuic acid," *Cancer*, vol. 75, no. 6, pp. 1433–1439, 1995.
- [74] Y. Nakamura, K. Torikai, Y. Ohto, A. Murakami, T. Tanaka, and H. Ohigashi, "A simple phenolic antioxidant protocatechuic acid enhances tumor promotion and oxidative stress in female ICR mouse skin: dose- and timing-dependent enhancement and involvement of bioactivation by tyrosinase," *Carcinogenesis*, vol. 21, no. 10, pp. 1899–1907, 2000.
- [75] T. Tanaka, Y. Yasui, M. Tanaka, T. Tanaka, T. Oyama, and K. W. Rahman, "Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats," *Chemico-Biological Interactions*, vol. 177, no. 2, pp. 128–136, 2009.

- [76] R. A. Sharma, A. L. Harris, A. G. Dalglish, W. P. Steward, and K. J. O'Byrne, "Angiogenesis as a biomarker and target in cancer chemoprevention," *The Lancet Oncology*, vol. 2, no. 12, pp. 726-732, 2001.
- [77] W. N. William Jr., J. V. Heymach, E. S. Kim, and S. M. Lippman, "Molecular targets for cancer chemoprevention," *Nature Reviews Drug Discovery*, vol. 8, no. 3, pp. 213-225, 2009.
- [78] G. M. Gorgdillo and C. K. Sen, "Hemangioidioma as a model to study the antiangiogenic effects of dietary chemopreventive agents in vivo," in *Phytopharmaceuticals in Cancer Chemoprevention*, D. Bagchi and H. G. Preuss, Eds., pp. 205-213, CRC Press, Boca Raton, Fla, USA, 2005.
- [79] J. Schoenfeld, K. Lessan, N. Johnson, et al., "Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF," *Angiogenesis*, vol. 7, no. 2, pp. 143-156, 2004.
- [80] W. W. Li, "Tumor angiogenesis as a target for early intervention and cancer prevention," in *Cancer Chemoprevention*, G. J. Kelloff, E. T. Hawk, and C. C. Sigman, Eds., vol. 1, pp. 611-633, Humana Press, Totowa, NJ, USA, 2004.
- [81] N. Khan, F. Afaq, and H. Mukhtar, "Apoptosis by dietary factors: the suicide solution for delaying cancer growth," *Carcinogenesis*, vol. 28, no. 2, pp. 233-239, 2007.
- [82] K. El-Bayoumy and R. Sinha, "Molecular chemoprevention by selenium: a genomic approach," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 591, no. 1-2, pp. 224-236, 2005.
- [83] H. Zhang, Y. Dong, H. Zhao, et al., "Microarray data mining for potential selenium targets in chemoprevention of prostate cancer," *Cancer Genomics and Proteomics*, vol. 2, no. 2, pp. 97-113, 2005.
- [84] O. Kitahara, Y. Furukawa, T. Tanaka, et al., "Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia," *Cancer Research*, vol. 61, no. 9, pp. 3544-3549, 2001.
- [85] F. P. Li, J. A. Fletcher, M. C. Heinrich, et al., "Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred," *Journal of Clinical Oncology*, vol. 23, no. 12, pp. 2735-2743, 2005.
- [86] J. T. Arnold, B. P. Wilkinson, S. Sharma, and V. E. Steele, "Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay," *Cancer Research*, vol. 55, no. 3, pp. 537-543, 1995.
- [87] E. A. Korytynski, G. J. Kelloff, W. A. Suk, S. Sharma, and E. Elmore, "The development of an anchorage-independence assay using human lung tumor cells to screen potential chemopreventive agents," *Anticancer Research*, vol. 16, no. 3A, pp. 1091-1094, 1996.
- [88] V. E. Steele, S. Sharma, R. Mehta, et al., "Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals," *Journal of Cellular Biochemistry*, vol. 63, no. S26, pp. 29-53, 1996.
- [89] H. A. Bern and S. Nandi, "Recent studies of the hormonal influence in mouse mammary tumorigenesis," *Progress in Experimental Tumor Research*, vol. 2, pp. 90-144, 1961.
- [90] C. J. Rudd, J. N. Mansbridge, K. D. Suing, and M. I. Dawson, "Correlation of the ability of retinoids to inhibit promoter-induced anchorage-independent growth of JB6 mouse epidermal cells with their activation of retinoic acid receptor γ ," *Cancer Letters*, vol. 73, no. 1, pp. 41-49, 1993.
- [91] E. Elmore, T.-T. Luc, H.-R. Li, et al., "Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data," *Anticancer Research*, vol. 20, no. 1A, pp. 27-32, 2000.
- [92] M. A. Pereira, L. H. Barnes, V. L. Rassman, G. V. Kelloff, and V. E. Steele, "Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents," *Carcinogenesis*, vol. 15, no. 5, pp. 1049-1054, 1994.
- [93] D. E. Corpet and S. Taché, "Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency," *Nutrition and Cancer*, vol. 43, no. 1, pp. 1-21, 2002.
- [94] H. J. Thompson, J. N. McGinley, K. Rothhammer, and M. Singh, "Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea," *Carcinogenesis*, vol. 16, no. 10, pp. 2407-2411, 1995.
- [95] R. P. Bird, "Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings," *Cancer Letters*, vol. 37, no. 2, pp. 147-151, 1987.
- [96] S. J. Alrawi, M. Schiff, R. E. Carroll, et al., "Aberrant crypt foci," *Anticancer Research*, vol. 26, no. 1A, pp. 107-119, 2006.
- [97] R. P. Bird, "Role of aberrant crypt foci in understanding the pathogenesis of colon cancer," *Cancer Letters*, vol. 93, no. 1, pp. 55-71, 1995.
- [98] R. P. Bird and C. K. Good, "The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer," *Toxicology Letters*, vol. 112-113, pp. 395-402, 2000.
- [99] R. G. Stevens, H. Swede, and D. W. Rosenberg, "Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies," *Cancer Letters*, vol. 252, no. 2, pp. 171-183, 2007.
- [100] V. E. Steele, R. C. Moon, R. A. Lubet, et al., "Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program," *Journal of Cellular Biochemistry*, vol. 56, no. S20, pp. 32-54, 1994.
- [101] B. Mognetti, F. Di Carlo, and G. N. Berta, "Animal models in oral cancer research," *Oral Oncology*, vol. 42, no. 5, pp. 448-460, 2006.
- [102] I. B. Gimenez-Conti and T. J. Slaga, "The hamster cheek pouch carcinogenesis model," *Journal of Cellular Biochemistry*, vol. 52, no. S17F, pp. 83-90, 1993.
- [103] X.-H. Tang, B. Knudsen, D. Bemis, S. Tickoo, and L. J. Gudas, "Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice," *Clinical Cancer Research*, vol. 10, no. 1, part 1, pp. 301-313, 2004.
- [104] D. Kanojia and M. M. Vaidya, "4-nitroquinoline-1-oxide induced experimental oral carcinogenesis," *Oral Oncology*, vol. 42, no. 7, pp. 655-667, 2006.
- [105] R. C. Moon, G. J. Kelloff, C. J. Detrisac, V. E. Steele, C. F. Thomas, and C. C. Sigman, "Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen," *Anticancer Research*, vol. 12, no. 4, pp. 1147-1153, 1992.
- [106] R. C. Moon, K. V. N. Rao, C. J. Detrisac, and G. J. Kelloff, "Hamster lung cancer model of carcinogenesis and chemoprevention," *Advances in Experimental Medicine and Biology*, vol. 320, pp. 55-61, 1992.
- [107] S. S. Hecht, "Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke," *Environmental*

- Health Perspectives*, vol. 105, supplement 4, pp. 955–963, 1997.
- [108] G. D. Stoner, "Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals," *Experimental Lung Research*, vol. 17, no. 2, pp. 405–423, 1991.
- [109] K. Guda, J. N. Marino, Y. Jung, K. Crary, M. Dong, and D. W. Rosenberg, "Strain-specific homeostatic responses during early stages of Azoxymethane-induced colon tumorigenesis in mice," *International Journal of Oncology*, vol. 31, no. 4, pp. 837–842, 2007.
- [110] J. D. Lambert, J. Hong, G. Y. Yang, J. Liao, and C. S. Yang, "Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations," *The American Journal of Clinical Nutrition*, vol. 81, supplement 1, pp. 284S–291S, 2005.
- [111] B. S. Reddy, "Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention," *Cancer Epidemiology Biomarkers and Prevention*, vol. 9, no. 3, pp. 239–247, 2000.
- [112] T. Tanaka, "Chemoprevention of colon carcinogenesis by non-nutritive compounds in foods," in *Carcinogenic and Anticarcinogenic Factors in Food*, G. Eisenbrand, A. D. Dayan, P. S. Elias, W. Grunow, and J. Schlatter, Eds., pp. 365–391, Wiley-VCH, Weinheim, Germany, 2000.
- [113] T. Tanaka, H. Kohno, R. Suzuki, Y. Yamada, S. Sugie, and H. Mori, "A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate," *Cancer Science*, vol. 94, no. 11, pp. 965–973, 2003.
- [114] Y. Yasui, R. Suzuki, S. Miyamoto, et al., "A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis," *International Journal of Cancer*, vol. 121, no. 10, pp. 2331–2339, 2007.
- [115] D. L. McCormick, C. B. Adamowski, A. Fiks, and R. C. Moon, "Lifetime dose-response relationships for mammary tumor induction by a single administration of *N*-methyl-*N*-nitrosourea," *Cancer Research*, vol. 41, no. 5, pp. 1690–1694, 1981.
- [116] K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg, "EP₂ and EP₄ receptors regulate aromatase expression in human adipocytes and breast cancer cells: evidence of a BRCA1 and p300 exchange," *The Journal of Biological Chemistry*, vol. 283, no. 6, pp. 3433–3444, 2008.
- [117] J. S. Tront, B. Hoffman, and D. A. Liebermann, "Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH₂-terminal kinase and p38 stress signaling resulting in apoptosis and senescence," *Cancer Research*, vol. 66, no. 17, pp. 8448–8454, 2006.
- [118] K. Subbaramaiah, L. R. Howe, E. R. Port, et al., "HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism," *Cancer Research*, vol. 66, no. 10, pp. 5504–5511, 2006.
- [119] C. Brisken and S. Duss, "Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective," *Stem Cell Reviews*, vol. 3, no. 2, pp. 147–156, 2007.
- [120] D. A. Proia and C. Kuperwasser, "Reconstruction of human mammary tissues in a mouse model," *Nature Protocols*, vol. 1, no. 1, pp. 206–214, 2006.
- [121] N. Ito, S. Fukushima, and H. Tsuda, "Carcinogenicity and modification of the carcinogenic response by BHA, BHT and other antioxidants," *Critical Reviews in Toxicology*, vol. 15, no. 2, pp. 109–150, 1985.
- [122] P. J. Becci, H. J. Thompson, J. M. Strum, C. C. Brown, M. B. Sporn, and R. C. Moon, "*N*-butyl-*N*-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 × DBA/2 F₁ mice as a useful model for study of chemoprevention of cancer with retinoids," *Cancer Research*, vol. 41, no. 3, pp. 927–932, 1981.
- [123] M. Yang, T. Tanaka, Y. Hirose, T. Deguchi, H. Mori, and Y. Kawada, "Chemopreventive effects of diosmin and hesperidin on *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice," *International Journal of Cancer*, vol. 73, no. 5, pp. 719–724, 1997.
- [124] D. L. McCormick and R. C. Moon, "Antipromotional activity of dietary *N*-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice," *Cancer Letters*, vol. 31, no. 2, pp. 133–138, 1986.
- [125] B. S. Warren and T. J. Slaga, "Mechanisms of inhibition of tumor progression," *Basic Life Sciences*, vol. 61, pp. 279–289, 1993.
- [126] J. DiGiovanni, "Multistage carcinogenesis in mouse skin," *Pharmacology and Therapeutics*, vol. 54, no. 1, pp. 63–128, 1992.
- [127] F. L. Meyskens Jr., P. J. Farmer, S. Yang, and H. Anton-Culver, "New perspectives on melanoma pathogenesis and chemoprevention," *Recent Results in Cancer Research*, vol. 174, pp. 191–195, 2007.
- [128] E. Elmore, A. Jain, S. Siddiqui, et al., "Development and characteristics of a human cell assay for screening agents for melanoma prevention," *Melanoma Research*, vol. 17, no. 1, pp. 42–50, 2007.
- [129] F. Beermann, A. Hunziker, and A. Foletti, "Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium," *Pigment Cell Research*, vol. 12, no. 2, pp. 71–80, 1999.
- [130] Y. E. Marín and S. Chen, "Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development," *Journal of Molecular Medicine*, vol. 82, no. 11, pp. 735–749, 2004.
- [131] M. Nakamura, D. J. Tobin, B. Richards-Smith, J. P. Sundberg, and R. Paus, "Mutant laboratory mice with abnormalities in pigmentation: annotated tables," *Journal of Dermatological Science*, vol. 28, no. 1, pp. 1–33, 2002.
- [132] G. J. Walker and N. K. Hayward, "Pathways to melanoma development: lessons from the mouse," *Journal of Investigative Dermatology*, vol. 119, no. 4, pp. 783–792, 2002.
- [133] L. Ha, E. P. Noonan, E. C. De Fabo, and G. Merlino, "Animal models of melanoma," *The Journal of Investigative Dermatology*, vol. 10, no. 2, pp. 86–88, 2005.
- [134] F. P. Noonan, J. Dudek, G. Merlino, and E. C. De Fabo, "Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events," *Pigment Cell Research*, vol. 16, no. 1, pp. 16–25, 2003.
- [135] F. P. Noonan, J. A. Recio, H. Takayama, et al., "Neonatal sunburn and melanoma in mice," *Nature*, vol. 413, no. 6853, pp. 271–272, 2001.
- [136] A. Wolnicka-Glubisz and F. P. Noonan, "Neonatal susceptibility to UV induced cutaneous malignant melanoma in a mouse model," *Photochemical and Photobiological Sciences*, vol. 5, no. 2, pp. 254–260, 2006.
- [137] E. C. De Fabo, F. P. Noonan, T. Fears, and G. Merlino, "Ultraviolet B but not ultraviolet A radiation initiates

- melanoma," *Cancer Research*, vol. 64, no. 18, pp. 6372–6376, 2004.
- [138] D. Tormo, A. Ferrer, E. Gaffal, et al., "Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation," *American Journal of Pathology*, vol. 169, no. 2, pp. 665–672, 2006.
- [139] C. Berking and M. Herlyn, "Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology," *Histology and Histopathology*, vol. 16, no. 2, pp. 669–674, 2001.
- [140] S. Mohapatra, D. Coppola, A. I. Riker, and W. J. Pledger, "Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma," *Molecular Cancer Research*, vol. 5, no. 2, pp. 145–151, 2007.
- [141] L.-K. Su, K. W. Kinzler, B. Vogelstein, et al., "Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene," *Science*, vol. 256, no. 5057, pp. 668–670, 1992.
- [142] W. Edelmann, K. Yang, M. Kuraguchi, et al., "Tumorigenesis in *Mlh1* and *Mlh1/Apc1638N* mutant mice," *Cancer Research*, vol. 59, no. 6, pp. 1301–1307, 1999.
- [143] T. Tanaka, H. Kohno, R. Suzuki, et al., "Dextran sodium sulfate strongly promotes colorectal carcinogenesis in *Apc^{Min/+}* mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms," *International Journal of Cancer*, vol. 118, no. 1, pp. 25–34, 2006.
- [144] H. Tsuda, M. Asamoto, T. Ochiya, et al., "High susceptibility of transgenic rats carrying the human *c-Ha-ras* proto-oncogene to chemically-induced mammary carcinogenesis," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 477, no. 1-2, pp. 173–182, 2001.
- [145] S. Miyamoto, Y. Yasui, M. Kim, et al., "A novel *rasH2* mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies," *Carcinogenesis*, vol. 29, no. 2, pp. 418–426, 2008.
- [146] R. Suzuki, H. Kohno, M. Suzui, et al., "An animal model for the rapid induction of tongue neoplasms in human *c-Ha-ras* proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies," *Carcinogenesis*, vol. 27, no. 3, pp. 619–630, 2006.
- [147] S. Ueda, K. Fukamachi, Y. Matsuoka, et al., "Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human *Ha-ras* oncogene in rat pancreas," *Carcinogenesis*, vol. 27, no. 12, pp. 2497–2510, 2006.
- [148] K. Kiguchi, S. Carbajal, K. Chan, et al., "Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma," *Cancer Research*, vol. 61, no. 19, pp. 6971–6976, 2001.
- [149] B. S. Reddy, "Strategies for colon cancer prevention: combination of chemopreventive agents," *Sub-Cellular Biochemistry*, vol. 42, pp. 213–225, 2007.
- [150] T. Tanaka, H. Makita, K. Kawabata, et al., "Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin," *Carcinogenesis*, vol. 18, no. 5, pp. 957–965, 1997.
- [151] T. A. Ratko, C. J. Detrisac, N. M. Dinger, C. F. Thomas, G. J. Kelloff, and R. C. Moon, "Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats," *Cancer Research*, vol. 49, no. 16, pp. 4472–4476, 1989.
- [152] C. V. Rao, K. Tokumo, J. Rigotty, E. Zang, G. Kelloff, and B. S. Reddy, "Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α -difluoromethylornithine, 16 α -fluoro-5-androsten-17-one, and ellagic acid individually and in combination," *Cancer Research*, vol. 51, no. 17, pp. 4528–4534, 1991.
- [153] B. S. Reddy, J. Nayini, K. Tokumo, J. Rigotty, E. Zang, and G. Kelloff, "Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L- α -difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet," *Cancer Research*, vol. 50, no. 9, pp. 2562–2568, 1990.
- [154] G. Shen, T. O. Khor, R. Hu, et al., "Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in *Apc^{Min/+}* mouse," *Cancer Research*, vol. 67, no. 20, pp. 9937–9944, 2007.
- [155] B. A. Narayanan, B. S. Reddy, M. C. Bosland, et al., "Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence," *Clinical Cancer Research*, vol. 13, no. 19, pp. 5965–5973, 2007.
- [156] T.-T. Chang and T.-C. Chou, "Rational approach to the clinical protocol design for drug combinations: a review," *Acta Paediatrica Taiwanica*, vol. 41, no. 6, pp. 294–302, 2000.
- [157] T.-C. Chou, "Preclinical versus clinical drug combination studies," *Leukemia and Lymphoma*, vol. 49, no. 11, pp. 2059–2080, 2008.
- [158] T.-C. Chou and P. Talalay, "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors," *Advances in Enzyme Regulation*, vol. 22, pp. 27–55, 1984.
- [159] T. C. Chou and P. Talalay, "A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems," *The Journal of Biological Chemistry*, vol. 252, no. 18, pp. 6438–6442, 1977.
- [160] T. Rabi and A. Bishayee, "Terpenoids and breast cancer chemoprevention," *Breast Cancer Research and Treatment*. In press.
- [161] J. Sudbø, M. Bryne, L. Mao, et al., "Molecular based treatment of oral cancer," *Oral Oncology*, vol. 39, no. 8, pp. 749–758, 2003.
- [162] J. R. Marshall, "Prevention of colorectal cancer: diet, chemoprevention, and lifestyle," *Gastroenterology Clinics of North America*, vol. 37, no. 1, pp. 73–82, 2008.
- [163] P. Greenwald, "From carcinogenesis to clinical interventions for cancer prevention," *Toxicology*, vol. 166, no. 1-2, pp. 37–45, 2001.
- [164] S. De Flora, A. Izzotti, F. D'Agostini, et al., "Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice," *Experimental Lung Research*, vol. 31, no. 1, pp. 19–35, 2005.
- [165] A. S. Tsao, E. S. Kim, and W. K. Hong, "Chemoprevention of cancer," *CA: A Cancer Journal for Clinicians*, vol. 54, no. 3, pp. 150–180, 2004.
- [166] W. B. Armstrong, T. H. Taylor, and F. L. Meyskens, "Can a marker be a surrogate for development of cancer, and would we know it if it exists?" *Recent Results in Cancer Research*, vol. 166, pp. 99–112, 2005.
- [167] S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia, and A. Corti, "Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers

- with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study," *Cancer Research*, vol. 66, no. 2, pp. 1234–1240, 2006.
- [168] R. Lieberman, "Evolving strategies for prostate cancer chemoprevention trials," *World Journal of Urology*, vol. 21, no. 1, pp. 3–8, 2003.
- [169] W. M. van Weerden and F. H. Schröder, "The use of PSA as biomarker in nutritional intervention studies of prostate cancer," *Chemico-Biological Interactions*, vol. 171, no. 2, pp. 204–211, 2008.
- [170] K. J. Auborn, S. Fan, E. M. Rosen, et al., "Indole-3-carbinol is a negative regulator of estrogen," *The Journal of Nutrition*, vol. 133, supplement 7, pp. 2470S–2475S, 2003.
- [171] D. Heber, "Multitargeted therapy of cancer by ellagitannins," *Cancer Letters*, vol. 269, no. 2, pp. 262–268, 2008.
- [172] J. D. Clarke, R. H. Dashwood, and E. Ho, "Multi-targeted prevention of cancer by sulforaphane," *Cancer Letters*, vol. 269, no. 2, pp. 291–304, 2008.
- [173] R. B. van Breemen and N. Pajkovic, "Multitargeted therapy of cancer by lycopene," *Cancer Letters*, vol. 269, no. 2, pp. 339–351, 2008.
- [174] A. A. Powolny and S. V. Singh, "Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds," *Cancer Letters*, vol. 269, no. 2, pp. 305–314, 2008.
- [175] I. M. Berquin, I. J. Edwards, and Y. Q. Chen, "Multi-targeted therapy of cancer by omega-3 fatty acids," *Cancer Letters*, vol. 269, no. 2, pp. 363–377, 2008.
- [176] V. Nandakumar, T. Singh, and S. K. Katiyar, "Multi-targeted prevention and therapy of cancer by proanthocyanidins," *Cancer Letters*, vol. 269, no. 2, pp. 378–387, 2008.
- [177] N. Khan and H. Mukhtar, "Multitargeted therapy of cancer by green tea polyphenols," *Cancer Letters*, vol. 269, no. 2, pp. 269–280, 2008.
- [178] S. Banerjee, Y. Li, Z. Wang, and F. H. Sarkar, "Multi-targeted therapy of cancer by genistein," *Cancer Letters*, vol. 269, no. 2, pp. 226–242, 2008.
- [179] K. Ramasamy and R. Agarwal, "Multitargeted therapy of cancer by silymarin," *Cancer Letters*, vol. 269, no. 2, pp. 352–362, 2008.
- [180] A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, "Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins," *Cancer Letters*, vol. 269, no. 2, pp. 199–225, 2008.
- [181] H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, "Curcumin: from ancient medicine to current clinical trials," *Cellular and Molecular Life Sciences*, vol. 65, no. 11, pp. 1631–1652, 2008.

REVIEW

Mouse models for the study of colon carcinogenesis

Daniel W. Rosenberg*, Charles Giardina¹ and Takuji Tanaka²

Center for Molecular Medicine and Colon Cancer Prevention Program, Neag Cancer Center, University of Connecticut Health Center, Farmington, CT 06030-3101, USA, ¹Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06213, USA and ²Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan

*To whom correspondence should be addressed. Tel: +1 860 679 8704; Fax: +1 860 679 7639; Email: Rosenberg@uchc.edu

The study of experimental colon carcinogenesis in rodents has a long history, dating back almost 80 years. There are many advantages to studying the pathogenesis of carcinogen-induced colon cancer in mouse models, including rapid and reproducible tumor induction and the recapitulation of the adenoma–carcinoma sequence that occurs in humans. The availability of recombinant inbred mouse panels and the existence of transgenic, knock-out and knock-in genetic models further increase the value of these studies. In this review, we discuss the general mechanisms of tumor initiation elicited by commonly used chemical carcinogens and how genetic background influences the extent of disease. We will also describe the general features of lesions formed in response to carcinogen treatment, including the underlying molecular aberrations and how these changes may relate to the pathogenesis of human colorectal cancer.

Rodent colon tumor models (history and overview)

The study of experimental colon carcinogenesis in rodents has had a remarkably long history, dating back almost 80 years (1). Perhaps the earliest published study of Lorenz *et al.* (2) demonstrated tumorigenesis in the forestomach and intestine of mice following feeding with the polycyclic aromatic hydrocarbon, methylcholanthrene. Lisco *et al.* (3) reported that feeding radioactive yttrium to rats induced a high proportion of colon tumors. Walpole *et al.* (4) reported that white rats given injections of 4-aminodiphenyl and 3,2-dimethyl-4-aminodiphenyl developed colon tumors. However, the most commonly used model for sporadic colorectal cancer (CRC) takes advantage of the organotropism of the colon carcinogens, 1,2-dimethylhydrazine (DMH) and azoxymethane (AOM). Identification of these carcinogens arose initially from an early population study of Guamanians in which hydrazines were reported to be possible colon carcinogens with the hydrazine source being consumed cycad flour (5). When large quantities of cycad flour were fed to rats, adenocarcinomas in the colon arose in some of the animals. The carcinogen in cycad flour was subsequently found to be cycasin, a form of methylazoxymethanol (MAM) (6).

DMH, a metabolic precursor of MAM, was used in several early studies to induce tumors in rats (7–9). Repetitive treatment with this

Abbreviations: AA, arachidonic acid; ACF, aberrant crypt foci; AOM, azoxymethane; Apc, adenomatous polyposis coli; BCAC, β -catenin-accumulated crypt; COX-2, cyclooxygenase-2; cPLA₂, cytosolic phospholipase A₂; CRC, colorectal cancer; DFMO, difluoromethylornithine; DMAB, 3,2'-dimethyl-4-aminobiphenyl; DMH, 1,2-dimethylhydrazine; DSS, dextran sodium sulfate; HCA, heterocyclic amine; IBD, inflammatory bowel disease; i.p., intraperitoneal; IQ, 2-amino-33-methylimidazo[4,5-f]quinoline; MAM, methylazoxymethanol; miRNA, microRNA; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; MNU, methylnitrosourea; ODC, ornithine decarboxylase; PGDH, 15-hydroxyprostaglandin dehydrogenase; PGE₂, prostaglandin E₂; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine; s.c., subcutaneous; TGF, transforming growth factor; TNF, tumor necrosis factor.

methylating agent was reported to produce colon tumors in rodents that exhibit many of the pathological features associated with the human disease (10–13). Thus, DMH has provided cancer researchers with a reproducible experimental system for studying 'sporadic' (non-familial) forms of CRC (14). However, AOM offers advantages over DMH, including enhanced potency and greater stability in dosing solution (15,16). Since then, several thousand studies using AOM have been published (17–19). We have used this mouse model extensively for 15 years and have compiled considerable data on sensitivity and lesion characteristics across a number of mouse lines (20–27).

The occurrence of spontaneously occurring cancers within the gastrointestinal tract of rodents is not as rare as might be expected. For example, Rowlatt *et al.* (28) described the occurrence of a wide range of tumors of the intestinal tract in aged C57BL/6 mice, although the majority of the lesions were located in the small intestine. Miwa *et al.* (29) reported 28 cases of spontaneous colon tumors in male Wistar rats. Vandenberghe *et al.* (30) in a study of *Campylobacter*-like bacteria reported 17 naturally occurring primary endophytic adenocarcinomas in the ascending colon of Wistar rats. An examination of animal husbandry also demonstrated the presence of adenocarcinomas in the ascending colon of ACI rats foster bred by an Osaka female rat, perhaps depending on milk factor and humidity (31). Newmark *et al.* (32) found that maintaining mice on a semipurified diet, referred to as the new Western diet, designed to recapitulate a human Western diet, was capable of inducing colon tumors in 42% of 18-month-old C57BL/6 mice. Richie *et al.* (33) recently showed an induction of colon tumors in p53 knockout mice by causing glutathione depletion with buthionine sulfoximine treatment.

In summary, there are a number of advantages to studying the pathogenesis of carcinogen-induced colon cancer in rodent models. The models are highly reproducible, they can be readily tested on animals with different genetic backgrounds and the pathogenesis recapitulates human CRC, at least at the early stages. Historically, the majority of colon carcinogenesis studies have been carried out in rats (34,35). However, the high frequency of tumors generated within the distal colon of mice, as well as the histogenesis of multiple adenomas with subsequent development of adenocarcinomas, also validate the importance of this species for studying the pathogenesis of colon cancer (36,37). An advantage of murine models is the availability of extensive genetic information on individual mouse lines, the existence of recombinant inbred mouse panels and the ever-increasing number of transgenic, knockout and knockin genetic models that are available for study. Thus, the focus of this review will be mainly on murine models. One notable disadvantage of these models is the general lack of invasive and metastatic phenotype. However, in general, rodent models recapitulate the adenoma–carcinoma sequence that is found in human CRC. They have been used extensively to study cancer chemoprevention agents and dietary factors, although we will not discuss these studies in detail. In this review, we will discuss the general mechanisms of tumor initiation by these agents, describe the general features of the lesions formed by them and describe how they relate to human CRC.

Genetic background modulates carcinogen-induced tumors in rodents

Strain sensitivity in mice

As in human populations, genetic background of laboratory animals is a significant component of organ-specific carcinogenesis. Genetically defined inbred mouse strains that differ in their sensitivity to colon carcinogens offer distinct advantages for studying organ-specific carcinogenesis (Table I). For example, AKR/J and DBA/2J mice have

Table I. Differential sensitivity to carcinogens across mouse lines

Strain ^a	Carcinogen	No. of tumors per mouse	References
A/J	DMH, AOM	9.2–41.6	(26,42,46,254,255)
STS/A	DMH	8.2–18.4	(56)
SWR/J	DMH, AOM	9.5–16	(26,41,42,255)
FVB/N	AOM	3.6	(37)
C57Bl/6 ^b	DMH, AOM, MAM acetate	0–5.5	(37,41,49,255–257)
BALB/cJ	AOM	1–2	(24,44,45)
ICR/HeA ^c	DMH	n.d.	(41,257)
DBA/2J	3-MC, DMH	0–1	(44,256,257)
AKR/J	DMH, AOM, MAM	<1.0	(26,37,38,42,44,46,255)
129/SV	AOM	0	(37)
BALB/cHeA	DMH	0	(56)

3-MC, methylcholanthrene.

^aTumor incidence in the most sensitive strain that typically approaches 100%.

^bTumor incidences in the C57Bl/6 line are dependent upon the particular subline (N, J and Ha), ranging from 10 to 85% (251). n.d., not determined.

^cIncidence was 100%, but total number of tumors per colon was not reported.

been shown to be relatively resistant to colon tumor development, whereas Balb/cHea and SWR/J are moderately sensitive and A/J, P/J, STS/A and ICR/Hea are highly sensitive to DMH (21,38–44). These reported differences, however, are often variable and probably the result of environmental conditions under which the animals are maintained. For example, in one study, the relatively resistant AKR strain was found to develop a high proportion of invasive tumors in 16/21 female mice exposed to DMH for 25 weeks (44). Interestingly, route of administration is also important and directly influences colon tumor incidence (45). Izumi *et al.* (45) compared the carcinogenicity of DMH when given by oral, intragastric and subcutaneous (s.c.) administration. The s.c. treatment was most effective at yielding organospecificity to the colon. Addressing the wide variation in dosing protocols, Bissahoyo *et al.* (46) reported that in A/J mice, s.c. injection of AOM yielded smaller tumors than following intraperitoneal (i.p.) delivery, a difference that was not observed in SWR/J mice.

Our laboratory has identified a panel of inbred mouse lines that differ markedly in their susceptibility to AOM at both early and late stages of tumorigenesis (21,27,47). SWR/J and A/J mice are remarkably sensitive to AOM exposure. For example, A/J mice develop up to 20 tumors in the distal colon, whereas tumors in AKR/J mice are very rare (25,27,37). These differences were also reported by Bissahoyo *et al.* (46) who confirmed the importance of AOM dosing regimens and environmental conditions on tumorigenesis in C57Bl/6J, DBA/2J, AKR/J, SWR/J and A/J mice. Such differential strain sensitivity to chemical carcinogens provides an excellent experimental tool for modeling interindividual sporadic cancer sensitivity that is evident within human populations.

A number of potential molecular mechanisms that may contribute to differential cancer sensitivity have been considered. These include rates of carcinogen activation/detoxification, the extent of acute DNA alkylation and the efficiency of repair (16). In addition, the balance between proliferation and apoptosis of initiated colon crypt cells has also been examined (39,47). Based on proliferation kinetics, it was suggested that AKR expresses a protective or resistance factor (repressor gene) that impedes progression of carcinogen-induced foci into colon tumors (39). Deschner *et al.* (48) further suggested that the differential sensitivity of inbred mice to MAM may be predicted by the acute colonic proliferative response to carcinogen exposure, in which the sensitive SWR/J colons demonstrated the largest expansion of the epithelial proliferative compartment and the resistant AKR/J colons the least.

A limited set of mouse progenitor strains are commonly used for constructing gene knockout and transgenic animals. As part of our long-standing interest in differential sensitivity to colon carcinogens, our laboratory established the AOM sensitivity of a panel of inbred

mouse lines (FVB/N, 129/SvJ, C57Bl/6J and BALB/CJ) that are commonly used for constructing knockout and transgenic mouse strains (37). We reported that FVB/N developed on average 3.6 tumors per mouse and Balb/C mice developed one tumor per mouse (Table I). The 129SvJ and C57Bl/6J mice failed to develop tumors after four weekly injections of AOM (37), although Diwan *et al.* (49) did report differences in sensitivity to DMH of a panel of C57Bl/6 sublines (N, J and Ha). Despite these differences in tumor multiplicity, however, tumors shared a similar morphology regardless of strain. Of note, there was a lack of invasiveness and metastasis in even the most sensitive strains, an observation that underlies the vast majority of murine colon tumor models (50).

Jacoby *et al.* (51) conducted a genetic analysis of colon cancer susceptibility to DMH in mice. Mice were selected for study based on their stark differences in sensitivity to DMH. The prediction was that DMH-induced carcinogenesis would be a phenotype controlled by several unlinked loci. Matings were performed between C57Bl/6Ha and ICR/Hea strains with DMH sensitivity of 0 versus 100%, respectively. Tumors were found in 40 of 122 progeny. Segregation analysis revealed that multiple loci contribute to the phenotype, but with significant linkage to a novel locus, *Ccs1* on chromosome 12. Subsequent analysis identified a DNA mismatch repair gene, *Mlh3*, that physically maps to *Ccs1*, although there were no mutations identified in the protein-coding region of the gene in either susceptible or resistant mouse strains (52).

Since a large number of laboratories are using carcinogens to induce colon tumors in mice, the question of intralaboratory variability and standardization has emerged. Bissahoyo *et al.* (46) assessed AOM-induced tumorigenesis in A/J, SWR/J and AKR/J mouse strains using a variety of dosing regimens, as well as dietary factors. Using A/J mice, these investigators confirmed the utility of using 10 mg/kg body wt of AOM to produce a maximal effect in terms of tumor multiplicity, size and penetrance (26,37,42) although the maximum effect was achieved with only four doses (46). Importantly, no sex-dependent differences were reported and *in utero* exposure to AOM was not found to be carcinogenic (46). Histologically, these investigators reported that in SWR/J tumors from the 8 week treatment group, there was increased tumor progression, and in 10% of the colons, there was evidence for local invasion through the basement membrane, suggesting that AOM may have tumor-promoting properties in addition to its known ability to initiate tumors.

Recombinant inbred lines

Inbred mouse lines have also been used to map susceptibility quantitative trait loci that influence colon cancer. The Demant laboratory developed a series of recombinant congenic mouse strains referred to as the Ccs/Dem that were made from BALB/cHeA and STS/A strains (53–55). Each substrain has a different random subset of ~12.5% of genes from STS/A and 87.5% of genes from BALB/cHeA (53). Using DMH, five susceptibility loci were identified (*Sccl1–Sccl5*) using 192 F2 mice between the susceptible recombinant congenic strain CsS-19 and BALB/c (56). A candidate for *Sccl1* was subsequently identified as protein tyrosine phosphatase receptor type-J (*Ptpnj*) (57). A follow-up study using AOM confirmed the original five *Sccl* loci and also mapped five additional new *Sccl* loci (*Sccl11–Sccl15*) (58). Interestingly, a different subset of susceptibility genes was involved in the formation of adenomas and premalignant aberrant crypt foci (ACF) (59). Recently, Sevignani *et al.* (60) reported that microRNA (miRNA) genes are frequently located near mouse cancer susceptibility loci. Using a genome-wide approach, these investigators compared the genomic position of mouse cancer susceptibility loci with the positions of a panel of mouse miRNAs. Using a random effect Poisson regression model, they reported that a statistically significant number of miRNAs are located close to tumor susceptibility loci. Overall, 41.9% of miRNAs were located <5 megabase from the peak of the closest locus. These data thus provide a catalog of miRNAs in inbred mice that could represent a new family of genes involved in the development of human solid tumors (60).




Fig. 1. Metabolism of AOM involves multiple transcriptionally regulated xenobiotic-metabolizing enzymes.

Apc^{Min/+} mice

One mouse line that has been used to a limited extent for carcinogenesis studies is the *Apc*^{Min/+} mouse strain, developed from the results of a germ line mutagenesis study with *N*-ethyl-*N*-nitrosourea combined with phenotypic screening (61). Although *Apc*^{Min/+} mice spontaneously form a large number of benign adenomas in the small intestine, colon tumors develop in fewer than half of the animals. AOM treatment, however, can increase tumor incidence in the colons of these mice by up to 6-fold (62,63), significantly decreasing the number of animals required for a single experiment. It should also be noted that the number of colon tumors formed in *Apc*^{Min/+} mice are significantly greater than that formed in wild-type C57BL/6 mice, which is a relatively resistant background (63). Although the number of studies in which AOM has been given to *Apc*^{Min/+} is limited, this model has proven to be useful for studying the effects of chemopreventive compounds (64), where differences in agent metabolism between the large and small intestine may prove to be important. The tumors that form in AOM-treated *Apc*^{Min/+} mice also have interesting genetic features as well. On most mouse strain backgrounds, AOM induces tumors with activating mutations in the *β-catenin* gene (see below). However, colon tumors formed in AOM-treated *Apc*^{Min/+} mice frequently undergo loss of heterozygosity at the normal *Apc* locus (62). Although it is not clear how AOM might promote loss of heterozygosity in this model, it is through this mechanism by which colon tumors frequently form in human familial adenomatous polyposis patients, which is an advantage of this model.

Metabolism of DMH and AOM

DMH and its metabolite, AOM, are procarcinogens that require metabolic activation to form DNA-reactive products (65–67). Metabolism of these compounds involves multiple xenobiotic-metabolizing enzymes (Figure 1), which proceeds through several *N*-oxidation and hydroxylation steps, including the formation of MAM following hydroxylation of AOM. The reactive metabolite, MAM, readily yields a methyl diazonium ion, which can alkylate macromolecules in the liver and colon (65,68,69), including the addition of methyl groups at the O⁶ or N⁷ position of guanine (O⁶-methyl-deoxyguanosine and N⁷-methyl-deoxyguanosine). MAM is a substrate of the nicotinamide adenine dinucleotide⁺-dependent dehydrogenase present in the colon and liver, suggesting that the active metabolite of MAM might be the corresponding aldehyde (70). A direct role for the alcohol-inducible cytochrome P-450 isoform, CYP2E1, in activation of AOM and MAM has been established (71). These metabolites of CYP2E1 are transported to the colon via the bloodstream. The ability

of AOM and DMH to target the colonic mucosa is probably a consequence of the relative stability of the hydroxylated metabolite, MAM (72); with a half-life of ~12 h, there is sufficient time for MAM to distribute to the colon (73). Further activation of blood-borne metabolites may then proceed via non-P450-dependent mechanisms, including possible oxidation of MAM, directly within the colon (71,74).

It was originally hypothesized that the differential sensitivity of mouse strains to DMH may be attributed to differential activation of the procarcinogen (26). Sohn *et al.* (71) suggested that MAM is activated by alcohol dehydrogenase directly in rat colon to its proximate mutagen, methyl diazonium ion. To determine whether this ultimate metabolic step is critical to the activation of MAM and strain sensitivity, our laboratory evaluated the capacity of colon cytosols to activate MAM in an *in vitro* system (75). Due to its reactivity, MAM was generated from MAM acetate by acetylcholinesterase immediately prior to use. However, colon cytosols isolated from 7-week-old sensitive or resistant mice (SWR/J and AKR/J mice, respectively) had only minimal capacity to metabolize MAM, even at the highest concentration of MAM tested (2 mM). This result suggests that metabolism of MAM occurs by processes in the mouse that are independent of colonic alcohol dehydrogenase (75). The primary promutagenic lesion produced by AOM is methylation at the O⁶ position of guanine (76). Maximum alkylation of target tissue DNA occurs 6–12 h after injection with DMH (77,78). To examine the possibility that differential sensitivity to DMH/AOM correlates with DNA methylation, Papanikolaou *et al.* (16) measured DNA adduct levels 6 h after exposure of mice to AOM (i.p. 20 mg/kg). Using both immunoslot blot and high-performance liquid chromatography-fluorescence analyses, adduct levels were found to be significantly higher (2- to 3-fold) in the colons of the resistant AKR/J mice 6 h after exposure. In a second experiment, adduct levels were slightly higher (1.4-fold) in the sensitive SWR/J colons at 12 h, but had been markedly reduced by 48 h, whereas in the AKR/J, levels were unchanged (16). Furthermore, incubation of colon microsomes with AOM and calf thymus DNA showed comparable levels of O⁶-methyl-deoxyguanosine, demonstrating equivalent metabolic capacity in both strains. From these experiments, it can be concluded that the differential strain sensitivity is not the result of differences in carcinogen metabolism, but instead probably involves subsequent carcinogenic steps such as tumor promotion.

Other colon carcinogens

In addition to MAM acetate, AOM and DMH, there are other carcinogens that induce colon tumors to varying extents, including: (i) heterocyclic amines (HCAs), e.g. 2-amino-1-methyl-6-phenylimidazo

[4,5-*b*]pyridine (PhIP) and 2-amino-3,3-dimethylimidazo[4,5-*f*]quinoline (IQ); (ii) aromatic amines, e.g. 3,2'-dimethyl-4-aminobiphenyl (DMAB) and (iii) alkylnitrosamide compounds, e.g. methylnitrosourea (MNU) and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG). These carcinogens are summarized in Table II. Earlier studies tested the carcinogenicity of these agents, and subsequent studies were performed to evaluate their effects on histogenesis, cell proliferation kinetics, interaction with genetic susceptibility traits, dietary components, fecal stream components (e.g. bile acids) and bacterial flora, among other factors (79,80). The spectrum of epithelial lesions including malignancies induced in the colon by these carcinogens is similar to neoplastic lesions observed within the human colon.

HCA's

The formation of mutagens upon broiling of fish and meat was first discovered by the Sugimura laboratory (81-83). Since then, considerable progress has been made in this field. For example, IQ, produced from food pyrolysis, was first isolated from broiled fish and subsequently from a variety of broiled or cooked fish and meat (84,85). IQ is a strong mutagen in *Salmonella typhimurium* and also induces mutations in Chinese hamster lung cells and hepatocellular carcinomas in rodents and non-human primates (86,87). IQ has genotoxic activity in different organs (88,89). Other cooked food mutagens include 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline, 2-amino-3,4-dimethylimidazo[4,5-*f*]quinoline and PhIP. Among a number of HCAs that have been demonstrated to be highly mutagenic and tumorigenic in rodent models, IQ and PhIP have received considerable attention because they demonstrate a multitarget organospecificity, with cancer induction in colon, mammary gland and prostate of rodents (90-92). The precursors of IQ-type HCAs are creatinine, amino acids and sugars in meat and fish (93). It has been shown that IQ requires metabolic activation by liver microsomes for conversion to its ultimate carcinogen, while forming high levels of DNA adducts in a number of organs (94,95).

Although it is not clear whether HCAs directly contribute to human carcinogenesis, it is certain that these compounds are present in cooked foods and thus pose a credible risk to human populations. For example, colon tumors were induced in male F344 rats by administering PhIP in the diet at 100 and 400 p.p.m. for 52 and 104 weeks (90,96). Although the incidence of colon tumors was ≈ 43 and 55% in animals given PhIP at 100 and 400 p.p.m., respectively, severe toxicity resulted from the PhIP feeding regimen. Other investigators have also utilized IQ and PhIP to induce colon tumors. The results of these studies indicate that tumor incidence is very low, ranging from 5 to 28% when these agents were administered in the diet for up to 52 weeks (97). Most of the tumors were localized to the small intestine (20%) and very few tumors were found in the colon (8%). Based on these findings, Nakagama *et al.* (98) developed a novel animal model to enhance the formation of colon lesions by using a combination of PhIP and a high-fat diet. Short-term intermittent feeding of 400 p.p.m. PhIP in combination with a high-fat diet resulted in accelerated tumor formation. Since HCAs may contribute to human colon cancer development, this latter model may be useful for inducing colon carci-

nogenesis in animal model systems and to investigate the chemopreventive activity of potential agents against colon carcinogenesis. Recently, Doi *et al.* (99) identified a set of PhIP-altered genes (e.g. *Stat1* and *VEGF*) in rat colon tumors by giving an initiating dose of AOM followed by varying doses of PhIP (up to 200 p.p.m.), a tumor-enhancing effect that was clearly dose dependent (100).

Following its administration, PhIP is rapidly absorbed from the alimentary tract and widely distributed throughout the body. PhIP is then metabolically activated by Phase I and Phase II enzymes mainly in the liver, similar to other HCAs, and probably in terminal target organs as well (82,101). As shown in Figure 2, cytochrome P450-mediated *N*-hydroxylation of PhIP occurs predominantly by CYP1A2 in liver microsomes (82,101). *N*-hydroxylated metabolites of PhIP bind covalently to DNA to form adducts, but are further metabolized by Phase II enzymes, namely *N*- and *O*-acetyltransferases (NAT1 and NAT2) and sulfotransferases, and are required to generate carcinogenic species. The Phase II enzymes add *N*-acetoxy or *N*-sulfonyl moieties to *N*-hydroxylated PhIP in the liver and partly in the terminal target organs, and arylnitrenium ions (R-NH⁺) derived from these metabolites react with DNA to generate PhIP-adducted bases (101), which can induce mutations. PhIP is also DNA reactive, wherein the exocyclic amino group of PhIP covalently binds to the C8 of the guanine base (dG-C8-PhIP). This is the major adduct found in calf thymus DNA reacted *in vitro* with *N*-acetoxy-PhIP (82,101) and is also found in DNA from rats exposed to PhIP. PhIP is detoxified primarily via glutathione and glutathione transferases. In addition, detoxification of *N*-hydroxylated PhIP occurs in the liver through the generation of glucuronate conjugates (102). In this case, glucuronate-conjugated PhIP is secreted into the bile, de-conjugated by gut flora and reabsorbed from the gut through enterohepatic circulation. As a result, the colonic mucosa may undergo repeated exposures to activated PhIP *in vivo*.

Aromatic amines

In 1941, Lorenz *et al.* (2) initially observed the chemical induction of intestinal tumors in mice fed with the polyaromatic hydrocarbons, dibenzanthracene or methylcholanthrene. The carcinogenic action of DMAB was first recorded by Walpole *et al.* (4), who described the induction of colon tumors in rats by s.c. administration of DMAB. The carcinogenic action of DMAB to produce colon tumors was also evaluated (103,104). A total of 20 weekly s.c. injections of DMAB to male F344 rats at a dose level of 50 mg/kg body wt induced multiple colon tumors in ~ 26 to 30% of animals fed with a low-fat diet and 74% of animals fed with a high-fat diet. DMAB induced both benign (adenomas) and malignant (adenocarcinomas with invasion into muscularis mucosa) epithelial neoplasms, with a multiplicity of 1.2-2.7 tumors per tumor-bearing rat. The adenocarcinomas observed were both histopathologically well differentiated and poorly differentiated. One of the major weaknesses of this model, however, is that it requires multiple injections of DMAB to induce colon tumors. On a molar equivalent basis, DMAB is less potent in rodent models than the series of compounds derived from DMH or AOM. Another weakness of this model system is the induction of neoplasms in various other tissues,

Table II. Summary of carcinogens used to induce colon cancer in rodents

Carcinogens	Route of administration	Species	References
MNNG	Rectal infusion, 0.5 ml of 0.25% MNNG solution/day \times 32	Rats (Donryu), females	(108)
MAM acetate	Rectal infusion, 1 mg MAM acetate in 0.5 ml deionized water/day \times 7, 14 or 26	Rats (Donryu), males	(258)
MAM acetate	i.p. 20 or 35 mg/kg body wt \times 1; intravenous, 35 mg/kg body wt \times 1	Rats (Sprague-Dawley), males	(259)
<i>N</i> -nitroso- <i>N</i> -butylurea	i.p. 75 or 150 mg/kg body wt \times 1	Mice (C57BL/6), males	(260)
Methylnitrosourea	Intrarectal, 2.5 mg/rat/week \times 2	Rats (F344), males	(261)
DMN-OAc	i.p. 0.1 mmol/kg body wt \times 1	Rats (Sprague-Dawley), males	(262)
PhIP	Diet, 400 p.p.m., 52 weeks	Rats (F344)	(96)
IQ	Diet, 300 p.p.m., 55 weeks (male), 72 weeks (female)	Rats (F344)	(263)
DMAB	s.c. 100 mg/kg, 20 weeks	Rats (F344)	(264)




Fig. 2. Metabolic pathway for PhIP activation and induced mutations.

such as adenocarcinomas of mammary glands in female rats, sarcomas of the salivary glands, squamous cell carcinomas of the ear duct and skin, forestomach squamous cell papillomas, sarcomas and lymphomas and urothelial carcinomas of urinary bladder (11,105,106).

Alkylnitrosamide compounds

MNNG and MNU are direct alkylating agents that do not require metabolic activation and thus are potent topical carcinogens (89). Intrarectal instillation of MNU or MNNG has been reported to induce colorectal tumors in rodent models (7,107–110). In rats and mice, most of the induced colonic tumors are sessile or polypoid lesions. Because biochemical activation is not required, these carcinogens are ideal for inducing colon tumors in animals and studying the modifying effects of xenobiotics without involving the metabolism of the initiating carcinogen (110). Intrarectal administration of MNNG at a dose rate of 1–3 mg/rat/week for 20 weeks induced colon tumors in 100% of male F344 rats, of which 43% tumors were adenocarcinomas and 57% were adenomas. The neoplasms were all located in the distal colon and rectum where MNNG and MNU were applied. The adenocarcinomas induced were mostly well-differentiated types with infiltration into the submucosa, whereas some were poorly differentiated showing mucinous cancer cells infiltrating into the submucosa. Metastases were not usually observed (111,112). Because MNNG and MNU given intrarectally selectively induce tumors in the distal colon and rectum, these models have been widely used. The major weakness of this model is that intrarectal injection poses a significant technical challenge, and quantification of carcinogens instilled intrarectally is difficult.

Chemically induced gene mutations

There are a number of pathways leading to colon cancer in humans, including the sporadic and FAP-associated adenoma–carcinoma sequence, hereditary non-polyposis colorectal cancer and colitis-related cancer, and each is driven by distinct molecular events (113,114). In human sporadic CRC, a large number of mutational events occur, and the ‘genomic landscape’ of human CRC has recently been described (115). Genomic sequencing of human CRCs has revealed frequent somatic mutations and deletions in a spectrum of tumor-related genes, including *K-Ras*, *adenomatous polyposis coli (Apc)* and *p53* (116). Chemical agents used to induce tumors in rodents target many of the same genes or related genetic pathways. In this section, we discuss the genetic alterations associated with colon carcinogenesis induced by chemical carcinogens in rodent models. In the section that follows, we

will focus on the effects of these mutations on a number of tumor-associated pathways.

A number of tumor-related genes are often targeted by colon carcinogens in rodent colon cancer models. One common genetic target in human and carcinogen-induced rodent CRC is the *K-Ras* gene. Jacoby *et al.* (117) showed that DMH caused *K-Ras* activating mutations (G to A) in 66% of colon carcinomas. Similar *K-Ras* mutations occurred in premalignant colonic mucosa in 2 of 11 rats by 15 weeks, suggesting that this was an early mutational event (117). Interestingly, this group further showed that only 2.5% of MNU-generated adenomas had this mutation, whereas 33% of carcinomas had a G to A transition in *K-Ras* (118). In AOM-induced lesions, *K-Ras* mutations are frequently observed, whereas *Apc* and *p53* mutations are less frequently found (20,119,120). These differences cannot be explained simply by species differences since *p53* mutations have been detected in MNU-induced rat colon tumors and *Apc* mutations have been found in PhIP-induced tumors (121,122). Furthermore, *K-Ras* mutations do not appear to be a feature of PhIP-induced colon tumors (123). It has also been reported that in the rat, PhIP treatment causes a specific guanine deletion at the 5′-GGGA-3′ site in the *Apc* gene, resulting in a protein truncation (121). These different mutations probably result from the types of DNA damage induced by the different carcinogens. AOM causes point mutations (G:C to A:T transversions) in the *K-Ras* gene (121,124,125), which may result from base misincorporation resulting from the *O*⁶-methyl-deoxyguanine adducts (65,126). Recently, Calcagno *et al.* (127) established an unequivocal role for *K-Ras* activation in neoplastic initiation and progression in mice. Transgenic mice in which an oncogenic *K-Ras* (G12D) allele was activated in the colon developed spontaneous ACF. Interestingly, the biological fate of these lesions was dependent upon the anatomical region of the colon in which they formed since oncogenic *K-Ras*-induced ACF were capable of progression only in the proximal colon (127). Thus, the differences in genetic mutations that arise in chemically induced colon tumor models are largely carcinogen specific. *K-Ras* activation appears to play an important role in the AOM and DMH models, whereas this pathway is not frequently targeted by PhIP. Conversely, MNU and PhIP have been shown to target *p53* and *Apc*, respectively.

A role for the β -catenin/T-cell factor (Tcf) pathway in carcinogen-induced rodent colon cancer models has been clearly established. Using immunohistochemistry, Maltzman *et al.* (128) were the first to show that loss of wild-type *Apc* protein occurs in AOM-induced mouse colon tumors. Takahashi *et al.* (129) reported pronounced cytoplasmic and nuclear β -catenin staining in AOM-induced rat colon tumors. single strand conformation polymorphism analysis of the glycogen synthase kinase-3 β phosphorylation consensus motif

revealed eight mutations in 6/8 carcinomas (129). A similar high frequency of β -catenin mutations were found in AOM-induced colon tumors in ICR mice (130). Using single strand conformation polymorphism analysis, Takahashi *et al.* (130) reported that 9/10 β -catenin mutations in colon tumors were G:C \rightarrow A:T transitions, with a concomitant increase in cytoplasmic and nuclear staining. Koesters *et al.* (131) tested the possibility that long-term treatment with a carcinogen may alter the mutational spectrum of β -catenin mutations in rat colon. Rats were treated for 20 weeks with DMH and β -catenin was sequenced. While mutations were found in 12/33 tumors (36%), only one mutation affected the codon 33 mutation cluster region, whereas 11/12 (>90%) of the mutations were G-C mutations at codon 41. The authors further speculate that codon 41 mutations may have greater oncogenic potential, but require a sustained carcinogenic exposure to enable selection in tumors (131). β -Catenin mutations have also been found in PhIP-induced rat colon tumors without *Apc* mutations (132). PhIP was also shown to induce β -catenin mutations in rat adenomas (133) and even in dysplastic ACF (134). Similarly, a high frequency of β -catenin mutations was found in rat colon tumors induced by IQ treatment (135). In mice, there is considerable evidence for both β -catenin mutation and alterations in cellular localization (130). Guda *et al.* (23) showed that in A/J mice, AOM treatment caused nuclear accumulation of β -catenin. The secondary bile acid, deoxycholic acid, has also recently been shown to increase nuclear β -catenin levels in the normally resistant AKR/J mice treated with AOM, an effect that was not associated with a loss of plasma membrane E-cadherin (22). However, in AOM-exposed *Apc^{Min}* mice, Suzui *et al.* (63) reported that mutations in the β -catenin gene are less contributory to tumorigenesis than in C57BL/6 wild-type mice, suggesting different genetic pathways for colon cancer development in this model. Shitashige *et al.* (136) have focused on the potential role of *splicing factor-1 (SFI1)*, a component of the β -catenin-Tcf-4 complex. They report that AOM treatment resulted in a significant increase in the volume and number of colon tumors in the *Sfi1* heterozygous mice (137). These results indicate that consistent with human colon cancers, the Wnt/Apc/ β -catenin-signaling pathway indeed plays an important role in chemical-induced rodent colon carcinogenesis.

A common genetic alteration found in human CRC that is not typically observed in rodent carcinogen models is a missense mutation of the *p53* gene (120,138–141). The *p53* gene remains unmutated, even though *p53* knockout animals have an increased sensitivity to AOM (142,143). Although the *p53* gene is sequence-normal in AOM-induced tumors, it is expressed at elevated levels, much like what is observed in *p53*-mutant lesions where the mutant *p53* cannot activate expression of its negative regulator, *Mdm2* (139), the analysis of *p53* target gene expression and DNA binding activity revealed that the overexpressed *p53* protein has extremely low activity. Although it is not entirely clear how the phenotypic repression of *p53* activity is accomplished in these tumors, evidence for a central role for *Mdm2* has been obtained (144). Therefore, with regard to the *p53* pathway, AOM-induced tumors may be a good model human CRC in which *p53* is normal (~50%), or lesions with a wild-type *p53* and overexpressed *Mdm2*, which have been estimated to account for 15% of human CRC (145).

Phenotypic changes associated with chemically induced colon carcinogenesis

As noted above, many of the cellular and biochemical defects found in human carcinomas are recapitulated in chemical-induced rodent models, supporting the use of experimental colon carcinogenesis in animal systems as a model for human disease. These defects include dysregulation of arachidonic acid (AA) metabolism, including elevated cyclooxygenase (COX-2) activity with concomitant prostaglandin E_2 production (22,146), alterations in ornithine decarboxylase (ODC) (147) and polyamine levels (148,149) and upregulation of a number of proinflammatory cytokines, including tumor necrosis factor (TNF)- α and interleukin-1 α/β (150). In this regard, the rodent carcinogen models have proven to be particularly useful for testing and studying anticancer agents that target overexpressed proteins in human colon cancers.

AA/COX-2 pathway

Cellular fatty acid metabolism and downstream signaling events play a critical role in colon carcinogenesis. Evidence suggests that the modulation of AA metabolism with Cox inhibitors [e.g. non-steroidal anti-inflammatory drugs (NSAIDs)] or dietary factors can be an effective approach for lowering colon cancer risk or preventing polyp recurrence (151–157). However, a number of important issues regarding how lipid-signaling pathways impact early and late stages of colon carcinogenesis remain unresolved. A better understanding of the mechanisms by which AA, AA metabolites and related lipid-signaling pathways affect colon carcinogenesis could greatly improve our ability to target appropriate patient populations and design more effective treatment protocols that reduce colon cancer risk. Rodent carcinogen models are well suited for studying the role of lipid signaling in colon cancer.

A number of studies have reported that colon carcinogens, particularly AOM, can increase COX-2 expression and consequently prostaglandin E_2 (PGE $_2$) levels within adenocarcinomas (130,158–163). Elevated COX-2 expression has been shown to occur throughout the carcinogenic process, beginning in rats within normal-appearing colonic mucosa as early as 1 week following AOM exposure, an effect that was enhanced by administration of a high-fat corn oil diet (163). Elevated levels of COX-2 in AOM-induced rat tumors were also shown by Rao *et al.* (164) using a high-fat diet containing mixed lipids. Dong *et al.* (159) reported elevated COX-2 expression in A/J mice 24 weeks after AOM treatment accompanied by increased PGE $_2$ levels. Importantly, the formation of carcinogen-induced colon lesions can be suppressed by NSAIDs or COX-2 inhibitors. For example, the COX-2 inhibitor NS-398 significantly reduced the number of ACF in rats given AOM (165). In addition, sulindac was shown to be effective against certain types of ACF, including β -catenin-accumulated crypt (BCAC) and hexosaminidase-negative foci in rats (166), whereas the selective COX-2 inhibitor, JTE-522, was shown to suppress total ACF counts in DMH-treated rats (167). This same group, however, reported that COX-2 inhibition was effective when applied during the initiation phase, but not the progression phase, of DMH-induced carcinogenesis (167). These findings are, however, in contrast to those reported by Reddy *et al.* (168) showing that Celecoxib treatment was effective throughout the carcinogenic process in rats. Finally, Riehl *et al.* (169) have shown that COX-1-derived PGE $_2$ may be important during early phases of colon carcinogenesis following AOM, possibly by affecting stem cell survival in response to acute damage.

Other components of the AA cascade have also been shown to affect colon cancer pathogenesis. For example, coordinate with the COXs, the secretory phospholipase and cytosolic phospholipase A_2 (cPLA $_2$) control the production of lipid mediators, including PGE $_2$, by regulating the release of AA from phospholipid membranes (170). Overexpression of cPLA $_2$ has been reported in cholangiocarcinomas, hepatomas, non-small cell lung cancers and small intestinal tumors (171–173). Using AOM, our laboratory reported a strict inverse relationship between cPLA $_2$ and COX-2 expression in human and murine colon tumors (159,174), with cPLA $_2$ levels reduced in neoplastic lesions at both the messenger RNA and protein level. We have also reported that genetic deletion of cPLA $_2$ dramatically enhances the tumorigenic effects of AOM in the colon of Balb/c mice (24). The mechanism for this enhanced tumor response may be related to impaired apoptosis within the colonic mucosa of cPLA $_2$ -deficient mice (24), an effect that is related to reduced ceramide production in this tissue, as initially proposed by Chan *et al.* (175).

15-Hydroxyprostaglandin dehydrogenase (15-PGDH), a prostaglandin-degrading enzyme that is regulated by epidermal growth factor receptor (EGFR) signaling through the transcription factor Snail, is down-regulated in colon cancer (176,177). Mann *et al.* (176) showed that pharmacologic disruption of EGFR signaling with erlotinib eliminated tumor growth in a xenograft model while restoring 15-PGDH expression and reducing intratumoral PGE $_2$ levels. Myung *et al.* (177) directly tested the role of 15-PGDH in carcinogenesis by generating 15-PGDH-null

mice on the otherwise colon carcinogen resistant C57Bl/6J background. As predicted, the absence of 15-PGDH resulted in a marked increase in susceptibility to AOM, both in the incidence of tumors as well as pre-cancerous ACF.

As an alternative approach to reduce the levels of PGE₂, without affecting the production of other prostaglandins, our laboratory recently tested the role of the terminal microsomal PGE₂ synthase 1, mPGES-1, on intestinal tumorigenesis (178). While mPGES-1 deletion caused a marked reduction in intestinal tumors in *Apc*-mutant mice, it also suppressed the formation and growth of ACF induced by AOM, suggesting that promotion associated with PGE₂ may also occur early in carcinogenesis (178). Reduced ACF size was associated with an attenuated nuclear translocation of β -catenin, demonstrating for the first time that PGE₂ may exert direct control over Wnt signaling *in vivo*.

ODC and polyamines

A number of biochemical pathways are altered in colon cancer cells to sustain the high cell proliferation rates observed within tumors (179,180). An important example of one pathway is cellular polyamine synthesis. Polyamines (putrescine, spermidine and spermine) are necessary for cell growth and proliferation. They exist primarily in complexes with RNA and their effect on cell proliferation is likely to arise in part from a stimulation of protein synthesis (181). ODC is the rate-limiting enzyme in polyamine synthesis that generates putrescine from the decarboxylation of ornithine. ODC is intimately involved in normal cellular proliferation and is likely to play a role in colon carcinogenesis (182,183). Increased ODC activity and polyamine synthesis is a phenomenon common to cells undergoing rapid proliferation, including colon cancer (reviewed in 184). As shown by Luk *et al.* (185), AOM treatment resulted in elevated ODC activity corresponding to early (initiation) and late (promotion) phases of cancer development. As shown by Pizzi *et al.* (186), AOM treatment caused an extension of the crypt proliferative compartment to the upper third of crypts with a corresponding upward shift of DNA-synthesizing cells. These proliferation abnormalities were accompanied by increased ODC activity. Since human colon cancers also display elevated levels of polyamine synthesis and ODC activity, it was reasoned that ODC inhibition by agents like difluoromethylornithine (DFMO) may be able to suppress colon cancer development. The rodent carcinogen models played a central role in demonstrating the effectiveness of DFMO for colon cancer prevention (187–189). DFMO was subsequently tested in combination with sulindac in clinical trials by Meyskens *et al.* (190) and was found to reduce the risk of recurrent colorectal adenomas by up to 95%, with relatively low levels of toxicity. The interaction with sulindac may stem in part from sulindac's ability to stimulate polyamine export from the cell (191). The common ODC phenotype of human and carcinogen-induced rodent colon cancers was therefore instrumental in the preclinical development of DFMO.

Transforming growth factor- β and other cytokines

The transforming growth factor (TGF)- β pathway has been demonstrated to play an important role in modulating colon carcinogenesis in humans (192). In the normal colon, TGF- β has an antiproliferative effect on epithelial cells, inducing growth arrest in G₁ and apoptosis (193–195). These antiproliferative effects are mediated through the type I and type II TGF- β receptors, which dimerize upon TGF- β binding leading to the activation of the transcriptional regulatory SMAD proteins, SMAD2, 3 and 4. TGF- β may also influence colon cancer development through its potent immunosuppressive activities (196). Disruption of the TGF- β pathway is often observed in human colon cancers with microsatellite instability. In these cancers, carcinogenesis proceeds through the silencing of genes involved in DNA mismatch repair, which leads to the generation of frame-shift mutations in TGF- β RII. TGF- β signaling may also become compromised in repair-competent colon cancers due to point mutations in TGF- β RII or mutations in post-receptor signaling molecules such as SMAD2 and SMAD4 (197–202).

Evidence has been obtained that this pathway becomes disrupted in carcinogen-induced rodent models and may be an important factor for

determining the sensitivity of different mouse species to AOM-induced carcinogenesis (203). Although the TGF- β RII is not mutated in the AOM model, the expression of this receptor is significantly downregulated in sensitive A/J mice, at both the messenger RNA and protein level (203). Repression of TGF- β RII may render epithelial cells insensitive to TGF- β -mediated growth arrest. AOM tumors are also deficient for processing latent TGF- β 1, with approximately half of the TGF- β 1 in the tumors present in an unprocessed, inactive form (204). Finally, inhibition of the TGF- β pathway in AOM tumors is supported by microarray analysis showing that many TGF- β -activated genes are not expressed at elevated levels in tumors (204). The AOM model therefore provides investigators interested in understanding the role of TGF- β signaling in colon cancer a tractable model in which to test different hypotheses.

TGF- β and other cytokines can have a profound, yet complex effect on colon cancer. TGF- β for example may suppress early stages of colon cancer, whereas its ability to stimulate stromal cells may ultimately promote cancer invasion and metastasis. Chemical-induced colon cancers in rodents support the expression of numerous cytokines. Furthermore, these tumors can be promoted by the application of inflammatory agents such as dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid. These rodent models are particularly well suited for analyzing the role of different cytokines and cytokine profiles in colon carcinogenesis. Using knockout mouse strains, Osa-wa *et al.* (205) obtained evidence that the cytokine profile of a Th2 inflammatory responses (as observed in ulcerative colitis patients) is generally tumor promoting. Specifically, interferon-gamma knockout mice had a heightened tumor response relative to interleukin-4-deficient animals. The role of other cytokines has also been explored, with TNF- α being a particularly intriguing case. Although TNF- α knockout mice are more susceptible to colonic inflammation than wild-type animals (206), TNF-R1 knockout animals are resistant to cancer development in the AOM/DSS model (207), suggesting that signaling through different receptors may strongly influence colon cancer development. The rodent carcinogen models promise to play a central role in refining our understanding of the highly complex role of the immune response and inflammatory cytokines in colon cancer.

Tumor progression in rodent models

Tumor histology

In a study from our laboratory (37), we described the histology of tumors in A/J, FVB/N and Balb/CJ mice treated with four to six injections of AOM (i.p.) and killed at 24 weeks after the last injection. In each of these carcinogen-sensitive strains, tumors were localized to the distal colon and could not be detected, either grossly or histologically within the proximal colon. Tumors were intramucosal, ranging in size from 2 to 8 mm diameter and were exophytic, polypoid and tan to red with irregular surfaces in all strains. In the A/J mouse, colons were covered by multiple, coalescing tumors with minimal intervening areas of macroscopically normal epithelium (37). This 'carpeting' of the distal colonic mucosa with tumors can present a challenge in that it is often difficult to identify normal adjacent mucosa for comparison. Histologically, the cellular morphology within tumors in the A/J, FVB/N and Balb/CJ mice show similarities. At higher magnification, the intramucosal, expansile tumors are hypercellular, comprised of large numbers of closely packed epithelial cells, arranged in crypt-like structures with occasional cystic lumina, loss of goblet cell differentiation and supported by fibrovascular stroma. A common histological feature of these murine tumors is the paucity of goblet cells as demonstrated by markedly reduced periodic acid Schiff staining (37). These tumor crypts are arranged in a disorganized manner with general loss of polarity and minimal infiltration of the lamina propria by isolated islands of tumor cells derived from the epithelial compartment. The nuclei are large, pseudostratified, hyperchromatic, finely stippled and elongate to oval with mild to moderate anisokaryosis. Moderate to high numbers of lymphocytes and neutrophils are found within the lesions. Few macrophages infiltrate the stroma of the

tumors but are present within the crypt lumina. It is interesting to note that the greatest degree of inflammatory cell infiltrate is present in tumors of the highly sensitive A/J mouse strain, suggesting a strong inflammatory component in the progression of these tumors (37).

In general, rodent colon tumor models tend to be non-metastatic and rarely show evidence of tumor cell invasion (50,111,112,208). However, in the study of Nambiar *et al.* (37), infiltrative cords of epithelial cells were occasionally found to breach the muscularis mucosa and another focal nest of epithelial cells were present in the submucosal lymphatics of one tumor, indicating that progression to infiltrating carcinoma is possible, although infrequent, in this model. Another tumor that was present in an A/J mouse at the recto-anal junction also showed infiltration into the submucosa. Finally, there was evidence of a squamous cell carcinoma at the recto-anal junction that infiltrates into the rectal wall, and large numbers of neutrophils were present in this tumor. Thus, while metastasis is rare in these rodent carcinogen models, the potential certainly exists that these behaviorally benign tumors can be promoted under certain conditions (e.g. genetically or through the use of tumor-promoting agents), although this potential application has yet to be fully exploited. Recently, Maggio-Price *et al.* (209) demonstrated environmental conditions that favor neoplastic progression in otherwise unaffected mice. *SMAD3*^{-/-} mice maintained free of Gram-negative enterohepatic *Helicobacter* spp. for up to 9 months do not develop colon cancer, whereas infection of these mice with *Helicobacter* was found to trigger colon cancer within the cecum of 50–66% of the animals as early as 5 weeks post-infection. Histologically, the majority of these tumors were found to be infiltrative mucinous adenocarcinomas with evidence of tumor cell penetration through the colon wall into the serosa and mesentery (209).

Preneoplastic lesions

The observation that chemical carcinogens may induce macroscopic alterations within the colonic epithelium has a long and interesting history. Initial descriptions of preneoplastic alterations within the colonic mucosa were made by Delapierre *et al.* (210) who monitored the descending colon of rats by transmission electron microscopy and observed preneoplastic lesions at 3 weeks after treatment with DMH. Wargovich *et al.* (211) reported a number of histological alterations, including mucin changes and alterations in crypt proliferation rates after four injections of DMH to C57BL/6J and CF1 mice. While these and other studies (18,212–214) have identified colon crypts with altered histology, it was not until Bird (215) developed a methodology that could readily identify and quantify macroscopic alterations on the surface of the colon that they referred to as ACF. Using methylene blue dye staining, it was found that carcinogen-induced cryptal lesions could be distinguished by their increased size, thicker epithelial lining and increased pericryptal zone (216). ACF are morphological lesions that represent an early stage in the stepwise progression of colon cancer (216,217). These surface abnormalities often appear in the distal colon within 2 weeks of carcinogen treatment. Sequential analyses suggest that these early lesions increase in size and multiplicity and often exhibit nuclear atypia and dysplasia (42,217–219). ACF also show increased proliferative activity, growth factor signaling and *K-Ras* mutations, suggesting that at least a subset of ACF are putative precursors of colon cancer (20,127). Human ACF share a similar morphology and are present in grossly normal-appearing colon tissue from patients with CRC (220,221). It has been suggested that the nature and order of acquired genetic changes can profoundly impact ACF morphology and likelihood of tumor progression (222,223).

Since these early observations, a number of other investigators have described subsets of ACF with various histological criteria, including hexosaminidase-altered foci, BCAC, flat dysplasia and mucin-depleted foci (reviewed in 219). The Pretlow laboratory (224,225) demonstrated a marked reduction in hexosaminidase activity in methacrylate-embedded aberrant crypts taken from the distal colons of F344 rats treated with AOM. Tsukamoto *et al.* (226) then examined

the transcription of the hexosaminidase α and β subunits in altered foci and reported that both markers were downregulated in aberrant crypts of DMH-treated rats. The same group then examined by scanning electron microscopy the three-dimensional structure of DMH-exposed rat colons and found that hexosaminidase-altered foci had abnormal budding within the middle of the crypt body, distinct from the symmetrical budding that occurred in hexosaminidase-normal crypts (227). BCAC, described initially by (228), are reportedly a premalignant lesion in the colon that lack some of the characteristic histological features of traditional ACF, but may have a greater likelihood for malignant transformation than ACF. When the frequency of BCAC was studied in AOM-exposed resistant and sensitive mouse strains, BCAC was found at a greater frequency in the distal colon of the sensitive strain at a site associated with subsequent tumor formation (229). On the other hand, ACF were more common in the proximal colon and occurred at a similar frequency in the sensitive and resistant strains, suggesting that BCAC may be a more reliable prognostic lesion (229). Mucin-depleted foci, originally characterized by their defective mucin production by the Caderni *et al.* (230,231), are dysplastic lesions that are found in the colons of carcinogen-exposed rats. These lesions are induced by DMH, have a higher degree of dysplasia than ACF, increase in response to tumor promoters such as cholic acid or heme-rich diets and carry alterations in the Wnt-signaling pathway, including mutations in β -catenin (232). In addition, it was shown that the cancer-preventing agent polyethylene glycol suppressed their growth, whereas a high-fat diet resulted in a modest increase in mucin-depleted foci/colon with no change in ACF density (233). Finally, Paulsen *et al.* (233) identified flat dysplastic ACF in the colons of *Apc*^{Min} mice that have different macroscopic characteristics than carcinogen-induced ACF, as well as histological features consistent with microadenomas. More recently, these investigators have identified flat dysplastic ACF in the colons of AOM-treated A/J mice, as well as F344 rats (234). In both species, these flat ACF grew more rapidly than classical elevated ACF, possibly as a result of Wnt activation and accelerated crypt multiplication. Although limited in numbers, flat dysplastic ACF appeared to be more likely to become tumors than the elevated ACF (234). Clearly, the expanding diversity of ACF identified in rodent carcinogen models provides researchers with exciting new tools for studying the earliest stages of CRC. Lesions characterized in these models may ultimately become useful for predicting cancer risk in humans.

AOM/DSS model

Colon cancer is the most serious complication associated with long-standing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease (235,236). The risk of CRC increases with the extent and duration of the disease. Several animal models have been reported that recapitulate many of the features associated with IBD. Perhaps the most commonly used mouse model employs DSS (237). CRC development in the DSS colitis model typically requires a relatively long exposure period or cycles of DSS administration, and the incidence and/or multiplicity of induced tumors are relatively low (238). Many studies have suggested that chronic or repeated mucosal inflammation may result in tumorigenesis through several proposed mechanisms. These mechanisms include induction of genetic mutations, increased cryptal cell proliferation, changes in crypt cell metabolism, changes in bile acid enterohepatic circulation and alterations in bacterial flora (239,240). CRC development following DSS-induced inflammation supports the hypothesis that chronic inflammation in IBD plays a critical role in epithelial malignant neoplasia in the large bowel (239). In inflammatory and/or angiogenic environments, superoxide anion may be produced by infiltrating mast cells (241) or macrophages (242) to facilitate cancer development.

For understanding the pathogenesis of IBD-related CRC, we developed a novel colitis-related mouse CRC model (a two-stage mouse colon carcinogenesis model) initiated with AOM and promoted by DSS (243). In this model, mice develop tumors after a relatively short-term DSS exposure, compared with DSS alone. Male Crj:CD-1 (ICR)

mice were given a single i.p. administration (10 mg/kg body wt) of AOM, followed by a 1 week oral exposure (2% in drinking water) to DSS (molecular weight 40 000). Within 20 weeks, numerous colonic neoplasms (adenocarcinomas, 100% incidence with a multiplicity of 5.60 ± 2.42 and adenomas, 38% incidence with a multiplicity of 0.20 ± 0.40) and dysplastic lesions were observed (Figure 3). Immunohistochemically, dysplasia and neoplasms showed positive staining for β -catenin, COX-2 and inducible nitric oxide synthase, but did not show evidence of p53 immunoreactivity. Thus, this novel mouse model combining AOM with DSS can be used for investigating colitis-related colon. Interestingly, numerous mast cells are found surrounding or within these carcinomas (243). Although the role of mast cells in IBD development is still a matter of debate (244,245), inducible nitric oxide synthase expression by these cells may be involved in IBD and IBD-related colon carcinogenesis (246).

Our recent studies on inflammation-related carcinogenesis, where mice received a single dose of various colon carcinogens (i.e. AOM, PhIP and DMH) followed by 1 week of exposure to 2% DSS, have shown a high incidence of tumor formation within 20 weeks (247,248). Importantly, we also observed differential sensitivities to AOM/DSS-induced colon carcinogenesis among four different mouse lines (BALB/c, C3H/HeN, C57BL/6N and DBA/2N) (249). When these mice were given a single i.p. injection of AOM (10 mg/kg body wt), followed by 1% DSS (wt/vol, molecular weight 36 000–50 000) in drinking water for 4 days, the incidence of colonic adenocarcinoma was 100% with a multiplicity of 7.7 ± 4.3 in Balb/c mice, whereas only 50% of C57BL/6N mice developed tumors with a multiplicity of 1.0 ± 1.2 . Moreover, only a few colonic adenomas, but no adenocarcinomas, developed in C3H/HeN or DBA/2N mice. The inflammation and immunohistochemical nitrotyrosine positivity score of mice treated with AOM and DSS were (in decreasing order) as follows: C3H/HeN > BALB/c = ICR > DBA/2N > C57BL/6N and BALB/c = ICR > C57BL/6N > C3H/HeN > DBA/2N, respectively. These findings suggest that susceptibility to AOM/DSS-induced colonic tumorigenesis may be directly influenced by the degree of nitrosative stress in colonic tissue.

In a dose–response study of DSS as a tumor promoter (249), male ICR mice were given a single i.p. injection of AOM (10 mg/kg body wt), followed by DSS (molecular weight 40 000) at dose levels ranging from 0.1 to 2% (wt/vol) in the drinking water for 1 week. At week 14, in the mice that received AOM and 2% DSS, the incidence and

multiplicity of colonic tubular adenoma (75% and 1.25 ± 1.26 per mouse) and adenocarcinoma (100%, 2.75 ± 2.22 per mouse) were the highest. Colon tumors did not develop in mice that received AOM + 0.25% DSS and AOM + 0.1% DSS, although dysplastic crypts were observed in these mice. Scoring of inflammation and nitrotyrosine immunoreactivity suggested that severe inflammation and nitrosative stress was caused by high doses (2 and 1%) of DSS. Thus, the tumor-promoting effect of DSS is dose dependent, occurring at 1% or higher, and the effect corresponds to the degree of inflammation and nitrosative stress, assessed in this study by increased (2-fold) nitrotyrosine immunoreactivity that was observed within a variety of cell types (neoplastic, cryptal and endothelial cells, as well as infiltrative mononuclear cells) within the colonic mucosa (249).

In a time–course study, sequential analysis of pathological alterations during carcinogenesis was conducted to determine the influence of inflammation on colon carcinogenesis. Male ICR mice were given a single i.p. injection of AOM (10 mg/kg body wt) followed by 2% (wt/vol) DSS for 7 days, starting 1 week after AOM exposure. Colon adenomas were identified in 2/5 mice at week 3 and colon adenocarcinomas developed in 2/5 mice at week 4. Tumor incidence gradually increased with time and reached 100% with a multiplicity of 6.20 ± 2.48 at week 6. At week 14, the multiplicity of adenocarcinomas was 9.75 ± 2.49 . In addition, colonic dysplasia was observed at all time points. The scores of colonic inflammation and nitrotyrosine immunohistochemistry were extremely high at early time points and were well correlated. These results indicate that the AOM/DSS model generates neoplasms that develop through dysplastic lesions in the colonic mucosa.

Although the incidence of colon tumors in *Apc^{Min/+}* mice is generally low, numerous colon tumors developed within 5 weeks in male and female *Apc^{Min/+}* mice when they received 2% DSS in drinking water for 7 days (248). Further molecular analysis revealed a high incidence (80–100%) of β -catenin gene mutations in AOM-induced colonic adenocarcinomas (247,248). In DMH/DSS-induced adenocarcinomas, 10 of 11 (90%) adenocarcinomas had β -catenin gene mutations. About half of the mutations were detected at codons 37 or 41 (247). In the AOM/DSS-induced colonic adenocarcinomas, mutations of the β -catenin gene were present in codons 32 to 34 (248). These mutations differ from those induced by AOM alone that were found in codons 33, 37 and 41 (130). From these findings and other reports (130,131), we postulate that mutations within codons 33 and 34 might




Fig. 3. (A) Protocol for AOM/DSS-induced colon carcinogenesis. Animals received a single i.p. injection (10 mg/kg body wt for AOM and 10 or 20 mg/kg body wt for DMH), or intragastric intubation (PhIP, 200 mg/kg body wt), followed by a 1 week exposure of DSS (1–2%) in drinking water to induce colonic neoplasms. Between 15 and 20 weeks, colon tumors in mice (B) and rats (C) develop. (D) Dysplastic crypts induced by the combination of AOM/DSS in mice. (E) Tubular adenoma induced by AOM/DSS in mice. (F) A representative tubular adenocarcinoma induced by AOM/DSS in mice. Scale bar = 60 μ m.

be caused by AOM exposure, whereas codon 32 mutations result from DSS exposure. Furthermore, we suggest that DSS promotes loss of *Apc* in the *Apc^{Min}* model.

Within the inflamed colon of mice that received a combination of AOM and DSS, gene expression was altered when compared with that of untreated mice or mice treated with either AOM or DSS alone (250). Global gene expression analysis was performed on normal-appearing colonic mucosa at weeks 5 and 10 following treatment. Significantly upregulated genes in the AOM/DSS group at week 5 include the Wnt inhibitory factor 1 (*Wif1*), plasminogen activator (*Plat*) and myelocytomatosis oncogene (*Myc*). At week 10, the level of phospholipase A₂ group IIA (platelets and synovial fluid) (*Plscr2*) was increased. The combination of AOM/DSS also resulted in the downregulation of the peroxisome proliferator activated receptor-binding protein (*Pparbp*) and the *Tgfb3* at 10 weeks. In addition, the inflammation-related gene, peroxisome proliferator activated receptor- γ (*Pparg*), was also downregulated at 5 weeks. The impact of these gene expression changes on cancer development has not yet been evaluated.

In summary, the AOM/DSS animal model has proven to be a powerful tool for investigating the pathogenesis and chemoprevention of colitis-related colon carcinogenesis. Modifications of this model might facilitate the detection of environmental carcinogens (251) and other tumor risk modifiers (252), as well as novel chemopreventive agents (253) against IBD-related CRC.

Funding

National Institutes of Health (5R01CA081428).

Acknowledgements

Conflict of Interest Statement: None declared.

References

- Krebs, C. (1928) Experimenteller Alkoholkrebs bei weissen Mäusen. *Z. Immun. Exp. Therap.*, **50**, 203–218.
- Lorenz, E. et al. (1941) Intestinal carcinoma and other lesions in mice following oral administration of 1,2,5,6-dibenzanthracene and 20-methyleholanthrene. *J. Natl Cancer Inst.*, **1**, 17–40.
- Lisco, H. et al. (1947) Carcinoma of the colon in rats following the feeding of radioactive yttrium. *Cancer Res.*, **7**, 721–725.
- Walpole, A.L. et al. (1952) The carcinogenic action of 4-aminodiphenyl and 3:2'-dimethyl-4-amino-diphenyl. *Br. J. Ind. Med.*, **9**, 255–263.
- Laqueur, G.L. et al. (1963) Carcinogenic Properties of nuts from *Cycas circinalis* L. indigenous to Guam. *J. Natl Cancer Inst.*, **31**, 919–951.
- Laqueur, G.L. (1964) Carcinogenic effects of cycad meal and cycasin, methylazoxymethanol glycoside, in rats and effects of cycasin in germfree rats. *Fed. Proc.*, **23**, 1386–1388.
- Druckrey, H. et al. (1967) Selective production of intestinal cancer in rats by 1,2-dimethylhydrazine. *Naturwissenschaften*, **54**, 285–286.
- Schauer, A. et al. (1969) Cancerization of the rat intestine by 1,2-dimethylhydrazine. *Z. Gesamte Exp. Med.*, **150**, 87–93.
- Thurnherr, N. et al. (1975) Induction of colonic carcinoma in mice using 1,2-dimethylhydrazine hydrochloride. *Schweiz. Med. Wochenschr.*, **105**, 585–586.
- Haase, P. et al. (1973) Histogenesis of colonic tumours in mice induced by dimethyl hydrazine. *J. Pathol.*, **109**, Px.
- Martin, M.S. et al. (1973) An experimental model for cancer of the colon and rectum. Intestinal carcinoma induced in the rat 1,2-dimethylhydrazine. *Digestion*, **8**, 22–34.
- Shamsuddin, A.K. et al. (1981) Preneoplastic and neoplastic changes in colonic mucosa in Crohn's disease. *Arch. Pathol. Lab. Med.*, **105**, 283–286.
- Ward, J.M. (1974) Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. *Lab. Invest.*, **30**, 505–513.
- LaMont, J.T. et al. (1978) Experimental colon cancer. *Gastroenterology*, **75**, 1157–1169.
- Neufert, C. et al. (2007) An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. *Nat. Protoc.*, **2**, 1998–2004.
- Papanikolaou, A. et al. (1998) Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. *Toxicol. Appl. Pharmacol.*, **150**, 196–203.
- Deschner, E.E. et al. (1977) Colonic neoplasms in mice produced with six injections of 1,2-dimethylhydrazine. *Oncology*, **34**, 255–257.
- Thurnherr, N. et al. (1973) Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine. *Cancer Res.*, **33**, 940–945.
- Toth, B. et al. (1976) Production of intestinal and other tumours by 1,2-dimethylhydrazine dihydrochloride in mice. II. Scanning electron microscopic and cytochemical study of colonic neoplasms. *Br. J. Exp. Pathol.*, **57**, 696–705.
- Bolt, A.B. et al. (2000) Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon. *Mol. Carcinog.*, **27**, 210–218.
- Delker, D.A. et al. (1999) Quantitative assessment of azoxymethane-induced aberrant crypt foci in inbred mice. *Exp. Mol. Pathol.*, **65**, 141–149.
- Flynn, C. et al. (2007) Deoxycholic acid promotes the growth of colonic aberrant crypt foci. *Mol. Carcinog.*, **46**, 60–70.
- Guda, K. et al. (2004) Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. *Oncogene*, **23**, 3813–3821.
- Ilsley, J.N. et al. (2005) Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. *Cancer Res.*, **65**, 2636–2643.
- Nambiar, P.R. et al. (2004) Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. *Cancer Res.*, **64**, 6394–6401.
- Papanikolaou, A. et al. (1998) Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. *Cancer Lett.*, **130**, 29–34.
- Papanikolaou, A. et al. (2000) Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis. *Carcinogenesis*, **21**, 133–138.
- Rowlatt, C. et al. (1969) Naturally occurring tumors and other lesions of the digestive tract in untreated C57BL mice. *J. Natl Cancer Inst.*, **43**, 1353–1364.
- Miwa, M. et al. (1976) Spontaneous colon tumors in rats. *J. Natl Cancer Inst.*, **56**, 615–621.
- Vandenbergh, J. et al. (1985) Spontaneous adenocarcinoma of the ascending colon in Wistar rats: the intracytoplasmic presence of a *Campylobacter*-like bacterium. *J. Comp. Pathol.*, **95**, 45–55.
- Miyamoto, M. et al. (1991) Adenocarcinoma in the ascending colon of ACI strain rat foster bred by WF-Osaka female rat. *Med. J. Osaka Univ.*, **40**, 1–3.
- Newmark, H.L. et al. (2001) A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. *Carcinogenesis*, **22**, 1871–1875.
- Richie, J.P.Jr et al. (2007) Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice. *Int. J. Oncol.*, **30**, 1539–1543.
- Madara, J.L. et al. (1983) Evidence for an adenoma-carcinoma sequence in dimethylhydrazine-induced neoplasms of rat intestinal epithelium. *Am. J. Pathol.*, **110**, 230–235.
- Weisburger, J.H. et al. (1977) Colon cancer: its epidemiology and experimental production. *Cancer*, **40**, 2414–2420.
- Chang, W.W. (1978) Histogenesis of symmetrical 1,2-dimethylhydrazine-induced neoplasms of the colon in the mouse. *J. Natl Cancer Inst.*, **60**, 1405–1418.
- Nambiar, P.R. et al. (2003) Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. *Int. J. Oncol.*, **22**, 145–150.
- Boffa, L.C. et al. (1980) Differences in colonic nuclear proteins of two mouse strains with different susceptibilities to 1, 2-dimethylhydrazine-induced carcinogenesis. *Cancer Res.*, **40**, 1774–1780.
- Deschner, E.E. et al. (1988) Susceptibility to 1,2-dimethylhydrazine-induced colonic tumors and epithelial cell proliferation characteristics of F1, F2, and reciprocal backcrosses derived from SWR/J and AKR/J parental mouse strains. *Cancer*, **61**, 478–482.
- Diwan, B.A. et al. (1979) Effects of methylazoxymethanol acetate on inbred mice: influence of genetic factors on tumor induction. *Proc. Soc. Exp. Biol. Med.*, **161**, 347–349.
- Evans, J.T. et al. (1977) Genetics of colon carcinogenesis in mice treated with 1,2-dimethylhydrazine. *Cancer Res.*, **37**, 134–136.
- Papanikolaou, A. et al. (2000) Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. *Carcinogenesis*, **21**, 1567–1572.
- Rosenberg, D.W. et al. (1995) Induction of aberrant crypts in murine colon with varying sensitivity to colon carcinogenesis. *Cancer Lett.*, **92**, 209–214.

44. Turusov, V.S. *et al.* (1982) Strain differences in susceptibility of female mice to 1,2-dimethylhydrazine. *Carcinogenesis*, **3**, 603–608.
45. Izumi, K. *et al.* (1979) Carcinogenicity of 1,2-dimethylhydrazine dihydrochloride in BALB/c mice. Influence of the route of administration and dosage. *Virchows Arch. A Pathol. Anat. Histol.*, **384**, 263–267.
46. Bissahoyo, A. *et al.* (2005) Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet. *Toxicol. Sci.*, **88**, 340–345.
47. Guda, K. *et al.* (2007) Strain-specific homeostatic responses during early stages of azoxymethane-induced colon tumorigenesis in mice. *Int. J. Oncol.*, **31**, 837–842.
48. Deschner, E.E. *et al.* (1984) Differential susceptibility of inbred mouse strains forecast by acute colonic proliferative response to methylazoxymethanol. *J. Natl Cancer Inst.*, **72**, 195–198.
49. Diwan, B.A. *et al.* (1980) Differential susceptibility of 3 sublines of C57BL/6 mice to the induction of colorectal tumors by 1,2-dimethylhydrazine. *Cancer Lett.*, **9**, 111–115.
50. Cespedes, M.V. *et al.* (2007) Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. *Am. J. Pathol.*, **170**, 1077–1085.
51. Jacoby, R.F. *et al.* (1994) Genetic analysis of colon cancer susceptibility in mice. *Genomics*, **22**, 381–387.
52. Lipkin, S.M. *et al.* (2000) MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. *Nat. Genet.*, **24**, 27–35.
53. Groot, P.C. *et al.* (1992) The recombinant congenic strains for analysis of multigenic traits: genetic composition. *FASEB J.*, **6**, 2826–2835.
54. Moen, C.J. *et al.* (1992) Scc-1, a novel colon cancer susceptibility gene in the mouse: linkage to CD44 (Ly-24, Pgp-1) on chromosome 2. *Oncogene*, **7**, 563–566.
55. van Wezel, T. *et al.* (1996) Gene interaction and single gene effects in colon tumour susceptibility in mice. *Nat. Genet.*, **14**, 468–470.
56. Moen, C.J. *et al.* (1996) Different genetic susceptibility to aberrant crypts and colon adenomas in mice. *Cancer Res.*, **56**, 2382–2386.
57. Ruivenkamp, C.A. *et al.* (2002) Ptpj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. *Nat. Genet.*, **31**, 295–300.
58. Ruivenkamp, C. *et al.* (2003) LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. *Oncogene*, **22**, 3472–3474.
59. Moen, C.J. *et al.* (1996) Fine mapping of colon tumor susceptibility (Scc) genes in the mouse, different from the genes known to be somatically mutated in colon cancer. *Proc. Natl Acad. Sci. USA*, **93**, 1082–1086.
60. Sevignani, C. *et al.* (2007) MicroRNA genes are frequently located near mouse cancer susceptibility loci. *Proc. Natl Acad. Sci. USA*, **104**, 8017–8022.
61. Moser, A.R. *et al.* (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science*, **247**, 322–324.
62. Mollersen, L. *et al.* (2004) Loss of heterozygosity and nonsense mutation in Apc in azoxymethane-induced colonic tumours in min mice. *Anticancer Res.*, **24**, 2595–2599.
63. Suzui, M. *et al.* (2002) Enhanced colon carcinogenesis induced by azoxymethane in min mice occurs via a mechanism independent of beta-catenin mutation. *Cancer Lett.*, **183**, 31–41.
64. Issa, A.Y. *et al.* (2007) Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. *Carcinogenesis*, **28**, 1978–1984.
65. Fiala, E.S. (1977) Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. *Cancer*, **40**, 2436–2445.
66. Fiala, E.S. *et al.* (1991) Mechanism of benzylselenocyanate inhibition of azoxymethane-induced colon carcinogenesis in F344 rats. *Cancer Res.*, **51**, 2826–2830.
67. Weisburger, J.H. (1971) Colon carcinogens: their metabolism and mode of action. *Cancer*, **28**, 60–70.
68. Fiala, E.S. *et al.* (1984) Non-alcohol dehydrogenase-mediated metabolism of methylazoxymethanol in the deer mouse, *Peromyscus maniculatus*. *Cancer Res.*, **44**, 2885–2891.
69. Fiala, E.S. *et al.* (1978) Inhibition of the metabolism of the colon carcinogen, azoxymethane, by pyrazole. *Cancer Res.*, **38**, 4515–4521.
70. Zedeck, M.S. *et al.* (1979) Metabolism of the colon carcinogen methylazoxymethanol acetate. *Front. Gastrointest. Res.*, **4**, 32–37.
71. Sohn, O.S. *et al.* (2001) Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. *Cancer Res.*, **61**, 8435–8440.
72. Nagasawa, H.T. *et al.* (1972) Decomposition of methylazoxymethanol, the aglycone of cycasin, in D 2 O. *Nature*, **236**, 234–235.
73. Feinberg, A. *et al.* (1980) Production of a highly reactive alkylating agent from the organospecific carcinogen methylazoxymethanol by alcohol dehydrogenase. *Cancer Res.*, **40**, 4446–4450.
74. Schoental, R. (1973) The mechanisms of action of the carcinogenic nitroso and related compounds. *Br. J. Cancer*, **28**, 436–439.
75. Delker, D.A. *et al.* (1998) The role of alcohol dehydrogenase in the metabolism of the colon carcinogen methylazoxymethanol. *Toxicol. Sci.*, **45**, 66–71.
76. Pegg, A.E. (1984) Methylation of the O6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. *Cancer Invest.*, **2**, 223–231.
77. Cooper, H.K. *et al.* (1978) DNA alkylation in mice with genetically different susceptibility to 1,2-dimethylhydrazine-induced colon carcinogenesis. *Cancer Res.*, **38**, 3063–3065.
78. Herron, D.C. *et al.* (1981) *In vivo* kinetics of O6-methylguanine and 7-methylguanine formation and persistence in DNA of rats treated with symmetrical dimethylhydrazine. *Cancer Res.*, **41**, 3967–3972.
79. Malt, R.A. *et al.* (1981) *Colonic Carcinogenesis*. Falk Symposium 31. MTP Press Ltd, Titisee, West Germany, pp. 1–406.
80. Scheppach, W. *et al.* (2003) *Exogenous Factors in Colonic Carcinogenesis*. Falk Symposium 128. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 1–324.
81. Nagao, M. *et al.* (1977) Mutagenicities of smoke condensates and the charred surface of fish and meat. *Cancer Lett.*, **2**, 221–226.
82. Sugimura, T. *et al.* (2004) Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. *Cancer Sci.*, **95**, 290–299.
83. Wakabayashi, K. *et al.* (1992) Food-derived mutagens and carcinogens. *Cancer Res.*, **52**, 2092s–2098s.
84. Barnes, W.S. *et al.* (1983) High pressure liquid chromatographic method for the analysis of 2-amino-3-methyl[4,5-f]imidazo quinoline, a mutagen formed from the cooking of food. *J. Agric. Food Chem.*, **31**, 883–886.
85. Felton, J.S. *et al.* (1984) Isolation and characterization of new mutagens from fried ground beef. *Carcinogenesis*, **5**, 95–102.
86. Adamson, R.H. *et al.* (1990) Carcinogenicity of 2-amino-3-methylimidazo [4,5-f]quinoline in nonhuman primates: induction of tumors in three macaques. *Jpn. J. Cancer Res.*, **81**, 10–14.
87. Sugimura, T. *et al.* (1990) Heterocyclic amines produced in cooked food: unavoidable xenobiotics. *Princess Takamatsu Symp.*, **21**, 279–288.
88. Tanaka, T. *et al.* (1985) Multipotential carcinogenicity of the fried food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in rats. *Jpn. J. Cancer Res.*, **76**, 570–576.
89. Weisburger, J.H. *et al.* (eds.) (1983) *Experimental Colon Carcinogenesis*. CRC Press, Boca Raton, FL.
90. Hasegawa, R. *et al.* (1993) Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenicity in rats. *Carcinogenesis*, **14**, 2553–2557. *
91. Ito, N. *et al.* (1997) Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat. *Mutat. Res.*, **376**, 107–114.
92. Shirai, T. *et al.* (1997) The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res.*, **57**, 195–198.
93. Grivas, S. *et al.* (1986) Isolation and identification of the food mutagens IQ and MeIQx from a heated model system of creatinine, glycine and fructose. *Food Chem.*, **20**, 127–136.
94. Kato, R. (1986) Metabolic activation of mutagenic heterocyclic aromatic amines from protein pyrolysates. *Crit. Rev. Toxicol.*, **16**, 307–348.
95. Schut, H.A. *et al.* (1988) DNA adduct formation of the carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in target tissues of the F-344 rat. *Cancer Lett.*, **41**, 345–352.
96. Ito, N. *et al.* (1991) A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis*, **12**, 1503–1506.
97. Reddy, B.S. *et al.* (1993) Inhibitory effect of *Bifidobacterium longum* on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. *Cancer Res.*, **53**, 3914–3918.
98. Nakagama, H. *et al.* (2005) Modeling human colon cancer in rodents using a food-borne carcinogen, PhIP. *Cancer Sci.*, **96**, 627–636.
99. Doi, K. *et al.* (2007) Altered gene expression in rat colonic adenocarcinomas induced in an azoxymethane plus 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine initiation-promotion model. *Oncology*, **73**, 252–260.
100. Doi, K. *et al.* (2005) Lack of large intestinal carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine at low doses in rats initiated with azoxymethane. *Int. J. Cancer*, **115**, 870–878.

101. Schut, H.A. *et al.* (1999) DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. *Carcinogenesis*, **20**, 353–368.
102. Felton, J.S. *et al.* (2002) Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. *Environ. Mol. Mutagen.*, **39**, 112–118.
103. Reddy, B.S. *et al.* (1981) Effect of intestinal microflora and dietary fat on 3,2'-dimethyl-4-aminobiphenyl-induced colon carcinogenesis in F344 rats. *Cancer Res.*, **41**, 1363–1367.
104. Spjut, H.J. *et al.* (1971) Experimental induction of tumors of the large bowel of rats. A review of the experience with 3-2' dimethyl-4-aminobiphenyl. *Cancer*, **28**, 29–37.
105. Decaens, C. *et al.* (1989) Induction of rat intestinal carcinogenesis with single doses, low and high repeated doses of 1,2-dimethylhydrazine. *Carcinogenesis*, **10**, 69–72.
106. Ward, J.M. (1975) Dose response to a single injection of azoxymethane in rats. Induction of tumors in the gastrointestinal tract, auditory sebaceous glands, kidney, liver and preputial gland. *Vet. Pathol.*, **12**, 165–177.
107. Narisawa, T. *et al.* (1974) Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in rats. *J. Natl Cancer Inst.*, **53**, 1093–1097.
108. Narisawa, T. *et al.* (1971) Carcinoma of the colon and rectum of rats by rectal infusion of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *Gann*, **62**, 231–234.
109. Narisawa, T. *et al.* (1975) Colon cancer induction in mice by intrarectal instillation of *N*-methylnitrosourea (38498). *Proc. Soc. Exp. Biol. Med.*, **148**, 166–169.
110. Reddy, B.S. *et al.* (1975) Animal models for the study of dietary factors and cancer of the large bowel. *Cancer Res.*, **35**, 3421–3426.
111. Heijstek, M.W. *et al.* (2005) Mouse models of colorectal cancer and liver metastases. *Dig. Surg.*, **22**, 16–25.
112. Kobaek-Larsen, M. *et al.* (2000) Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. *Comp. Med.*, **50**, 16–26.
113. Miyamoto, A. *et al.* (2007) Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. *Prev. Med.*, **44**, 12–19.
114. Yasui, Y. *et al.* (2007) Molecular mechanism of colorectal carcinogenesis. In Tanaka, T. (ed.) *Cancer: Disease Progression and Chemoprevention*. Reseach Signpost, Kerala, India, pp. 45–56.
115. Wood, L.D. *et al.* (2007) The genomic landscapes of human breast and colorectal cancers. *Science*, **318**, 1108–1113.
116. Takahashi, M. *et al.* (2004) Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. *Cancer Sci.*, **95**, 475–480.
117. Jacoby, R.F. *et al.* (1991) Mutations in the *K*-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. *J. Clin. Invest.*, **87**, 624–630.
118. Jacoby, R.F. *et al.* (1992) *K*-ras oncogene mutations in rat colon tumors induced by *N*-methyl-*N*-nitrosourea. *Carcinogenesis*, **13**, 45–49.
119. De Filippo, C. *et al.* (1998) Mutations of the *Apc* gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats. *Br. J. Cancer*, **77**, 2148–2151.
120. Erdman, S.H. *et al.* (1997) Assessment of mutations in *Ki*-ras and *p53* in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. *Mol. Carcinog.*, **19**, 137–144.
121. Kakiuchi, H. *et al.* (1995) Specific 5'-GGGA-3'→5'-GGA-3' mutation of the *Apc* gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine. *Proc. Natl Acad. Sci. USA*, **92**, 910–914.
122. Matsumoto, K. *et al.* (1997) Demonstration of *ras* and *p53* gene mutations in carcinomas in the forestomach and intestine and soft tissue sarcomas induced by *N*-methyl-*N*-nitrosourea in the rat. *Jpn. J. Cancer Res.*, **88**, 129–136.
123. Kakiuchi, H. *et al.* (1993) Rare frequency of activation of the *Ki*-ras gene in rat colon tumors induced by heterocyclic amines: possible alternative mechanisms of human colon carcinogenesis. *Mol. Carcinog.*, **8**, 44–48.
124. Stopera, S.A. *et al.* (1992) Evidence for a *ras* gene mutation in azoxymethane-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. *Carcinogenesis*, **13**, 2081–2085.
125. Vivona, A.A. *et al.* (1993) *K*-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. *Carcinogenesis*, **14**, 1777–1781.
126. Rogers, K.J. *et al.* (1977) Formation of O6-methylguanine by alkylation of rat liver, colon, and kidney DNA following administration of 1,2-dimethylhydrazine. *Cancer Res.*, **37**, 4082–4087.
127. Calcagno, S.R. *et al.* (2008) Oncogenic *K*-ras promotes early carcinogenesis in the mouse proximal colon. *Int. J. Cancer*, **122**, 2462–2470.
128. Maltzman, T. *et al.* (1997) AOM-induced mouse colon tumors do not express full-length *APC* protein. *Carcinogenesis*, **18**, 2435–2439.
129. Takahashi, M. *et al.* (1998) Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. *Cancer Res.*, **58**, 42–46.
130. Takahashi, M. *et al.* (2000) Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. *Carcinogenesis*, **21**, 1117–1120.
131. Koesters, R. *et al.* (2001) Predominant mutation of codon 41 of the beta-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol. *Carcinogenesis*, **22**, 1885–1890.
132. Dashwood, R.H. *et al.* (1998) High frequency of beta-catenin (*ctnbl*) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. *Cancer Res.*, **58**, 1127–1129.
133. Tsukamoto, T. *et al.* (2000) More frequent beta-catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP)-treated rats. *Jpn. J. Cancer Res.*, **91**, 792–796.
134. Ochiai, M. *et al.* (2003) Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine. *Am. J. Pathol.*, **163**, 1607–1614.
135. Blum, C.A. *et al.* (2003) Mutational analysis of *Ctnb1* and *Apc* in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-*f*]quinoline: mutational 'hotspots' and the relative expression of beta-catenin and *c-jun*. *Mol. Carcinog.*, **36**, 195–203.
136. Shitashige, M. *et al.* (2007) Involvement of splicing factor-1 in beta-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. *Gastroenterology*, **132**, 1039–1054.
137. Shitashige, M. *et al.* (2007) Increased susceptibility of *Sfl1*(+/-) mice to azoxymethane-induced colon tumorigenesis. *Cancer Sci.*, **98**, 1862–1867.
138. Makino, H. *et al.* (1994) Absence of *p53* mutations in rat colon tumors induced by 2-amino-6-methyldipyrro[1,2-*a*:3',2'-*d*]imidazole, 2-amino-3-methylimidazo[4,5-*f*]quinoline, or 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine. *Jpn. J. Cancer Res.*, **85**, 510–514.
139. Nambiar, P.R. *et al.* (2002) Role of the alternating reading frame (P19)-*p53* pathway in an *in vivo* murine colon tumor model. *Cancer Res.*, **62**, 3667–3674.
140. Shivapurkar, N. *et al.* (1995) Absence of *p53* gene mutations in rat colon carcinomas induced by azoxymethane. *Cancer Lett.*, **96**, 63–70.
141. Toyota, M. *et al.* (1996) Genetic alterations in rat colon tumors induced by heterocyclic amines. *Cancer*, **77**, 1593–1597.
142. Hu, Y. *et al.* (2005) Absence of acute apoptotic response to genotoxic carcinogens in *p53*-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. *Int. J. Cancer*, **115**, 561–567.
143. Tyner, S.D. *et al.* (1999) Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type *p53*. *Mol. Carcinog.*, **24**, 197–208.
144. Aizu, W. *et al.* (2006) Circumvention and reactivation of the *p53* oncogene checkpoint in mouse colon tumors. *Biochem. Pharmacol.*, **72**, 981–991.
145. Tachibana, M. *et al.* (2004) Dysfunction of *p53* pathway in human colorectal cancer: analysis of *p53* gene mutation and the expression of the *p53*-associated factors *p14ARF*, *p33ING1*, *p21WAF1* and *MDM2*. *Int. J. Oncol.*, **25**, 913–920.
146. Kawamori, T. *et al.* (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. *Carcinogenesis*, **24**, 985–990.
147. Tempero, M. (1986) Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. *Dig. Dis.*, **4**, 49–56.
148. Milovic, V. *et al.* (2003) Polyamines and colon cancer. *Biochem. Soc. Trans.*, **31**, 381–383.
149. Tanaka, T. *et al.* (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. *Carcinogenesis*, **18**, 957–965.
150. Yoshimi, N. *et al.* (1994) Expression of cytokines, TNF-alpha and IL-1 alpha, in MAM acetate and 1-hydroxyanthraquinone-induced colon carcinogenesis of rats. *Carcinogenesis*, **15**, 783–785.
151. Arber, N. *et al.* (2006) Celecoxib for the prevention of colorectal adenomatous polyps. *N. Engl. J. Med.*, **355**, 885–895.
152. Gupta, R.A. *et al.* (2000) Combinations for cancer prevention. *Nat. Med.*, **6**, 974–975.
153. Hallak, A. *et al.* (2003) Rofecoxib reduces polyp recurrence in familial polyposis. *Dig. Dis. Sci.*, **48**, 1998–2002.
154. Hawk, E. *et al.* (2007) The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. *Cancer Epidemiol. Biomarkers Prev.*, **16**, 185–187.
155. Janne, P.A. *et al.* (2000) Chemoprevention of colorectal cancer. *N. Engl. J. Med.*, **342**, 1960–1968.